The	O
myeloid-cell-specific	B-DNA
c-fes	I-DNA
promoter	I-DNA
is	O
regulated	O
by	O
Sp1	B-protein
,	O
PU.1	B-protein
,	O
and	O
a	O
novel	O
transcription	B-protein
factor	I-protein
.	O

The	O
protein	O
product	O
of	O
the	O
c-fps/fes	B-DNA
(	I-DNA
c-fes	I-DNA
)	I-DNA
proto-oncogene	I-DNA
has	O
been	O
implicated	O
in	O
the	O
normal	O
development	O
of	O
myeloid	B-cell_type
cells	I-cell_type
(	O
macrophages	B-cell_type
and	O
neutrophils	B-cell_type
)	O
.	O

mRNA	O
for	O
c-fes	O
has	O
been	O
detected	O
exclusively	O
in	O
myeloid	B-cell_type
cells	I-cell_type
and	O
vascular	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
in	O
adult	O
mammals	O
.	O

Although	O
a	O
13-kilobase-pair	B-DNA
(	I-DNA
kb	I-DNA
)	I-DNA
human	I-DNA
c-fes	I-DNA
transgene	I-DNA
exhibits	O
high	O
levels	O
of	O
expression	O
in	O
mice	O
,	O
the	O
sequences	O
that	O
confer	O
myeloid-cell-specific	O
expression	O
of	O
the	O
human	B-DNA
c-fes	I-DNA
gene	I-DNA
have	O
not	O
been	O
defined	O
.	O

Transient-transfection	O
experiments	O
demonstrated	O
that	O
plasmids	B-DNA
containing	O
446	O
bp	O
of	O
c-fes	B-DNA
5'-flanking	I-DNA
sequences	I-DNA
linked	O
to	O
a	O
luciferase	O
reporter	O
gene	O
were	O
active	O
exclusively	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

No	O
other	O
DNA	O
element	O
within	O
the	O
13-kb	B-DNA
human	I-DNA
c-fes	I-DNA
locus	I-DNA
contained	O
positive	B-DNA
cis-acting	I-DNA
elements	I-DNA
,	O
with	O
the	O
exception	O
of	O
a	O
weakly	O
active	O
region	O
within	O
the	O
3'-flanking	B-DNA
sequences	I-DNA
.	O

DNase	O
I	O
footprinting	O
assays	O
revealed	O
four	O
distinct	O
sites	O
that	O
bind	O
myeloid	B-protein
nuclear	I-protein
proteins	I-protein
(	O
-408	B-DNA
to	I-DNA
-386	I-DNA
,	O
-293	B-DNA
to	I-DNA
-254	I-DNA
,	O
-76	B-DNA
to	I-DNA
-65	I-DNA
,	O
and	O
-34	B-DNA
to	I-DNA
+3	I-DNA
)	O
.	O

However	O
,	O
the	O
first	O
two	O
footprints	O
resided	O
in	O
sequences	O
that	O
were	O
largely	O
dispensable	O
for	O
transient	O
activity	O
.	O

Plasmids	O
containing	O
151	B-DNA
bp	I-DNA
of	O
5'-flanking	B-DNA
sequences	I-DNA
confer	O
myeloid-cell-specific	O
gene	O
expression	O
.	O

Electrophoretic	O
mobility	O
shift	O
analyses	O
demonstrated	O
that	O
the	O
151-bp	B-DNA
region	I-DNA
contains	O
nuclear	B-DNA
protein	I-DNA
binding	I-DNA
sites	I-DNA
for	O
Sp1	B-protein
,	O
PU.1	B-protein
,	O
and/or	O
Elf-1	B-protein
,	O
and	O
a	O
novel	B-protein
factor	I-protein
.	O

This	O
unidentified	O
factor	O
binds	O
immediately	O
3	O
'	O
of	O
the	O
PU.1/Elf-1	B-DNA
sites	I-DNA
and	O
appears	O
to	O
be	O
myeloid	O
cell	O
specific	O
.	O

Mutation	O
of	O
the	O
PU.1	B-protein
/Elf-1	B-protein
site	O
or	O
the	O
3	B-DNA
'	I-DNA
site	I-DNA
(	O
FP4-3	B-DNA
'	I-DNA
)	O
within	O
the	O
context	O
of	O
the	O
c-fes	B-DNA
promoter	I-DNA
resulted	O
in	O
substantially	O
reduced	O
activity	O
in	O
transient	O
transfections	O
.	O

Furthermore	O
,	O
transient-cotransfection	O
assay	O
demonstrated	O
that	O
PU.1	B-protein
(	O
and	O
not	O
Elf-1	B-protein
)	O
can	O
transactivate	O
the	O
c-fes	B-DNA
promoter	I-DNA
in	O
nonmyeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
conclude	O
that	O
the	O
human	B-DNA
c-fes	I-DNA
gene	I-DNA
contains	O
a	O
strong	O
myeloid-cell-specific	B-DNA
promoter	I-DNA
that	O
is	O
regulated	O
by	O
Sp1	B-protein
,	O
PU.1	B-protein
,	O
and	O
a	O
novel	O
transcription	B-protein
factor	I-protein
.	O

MoLECULAR	NULL
AND	NULL
CELLULAR	NULL
BroLoGYy	NULL
,	NULL
Apr	NULL
.	NULL

1996	NULL
,	NULL
p.	NULL
1676-1686	NULL
0270-7306/96/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1996	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

16	NULL
,	NULL
No	NULL
.	NULL

4	NULL
The	NULL
Myeloid-Cell-Specific	NULL
c-fes	NULL
Promoter	NULL
Is	NULL
Regulated	NULL
by	NULL
Sp1	NULL
,	NULL
PU.1	NULL
,	NULL
and	NULL
a	NULL
Novel	NULL
Transcription	NULL
Factor	NULL
AHLKE	NULL
HEYDEMANN	NULL
,	NULL
'	NULL
GEORGE	NULL
JUANG	NULL
,	NULL
``	NULL
KATHLEEN	NULL
HENNESSY	NULL
,	NULL
**	NULL
MICHAEL	NULL
S.	NULL
PARMACEK	NULL
,	NULL
``	NULL
anp	NULL
M.	NULL
CELESTE	NULL
SIMON®*	NULL
>	NULL
*	NULL
Department	NULL
of	NULL
Molecular	NULL
Genetics	NULL
and	NULL
Cell	NULL
Biology	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
``	NULL
and	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
``	NULL
University	NULL
of	NULL
Chicago	NULL
,	NULL
Chicago	NULL
,	NULL
Illinois	NULL
60637	NULL
Received	NULL
18	NULL
October	NULL
1995/Returned	NULL
for	NULL
modification	NULL
4	NULL
December	NULL
1995/Accepted	NULL
21	NULL
December	NULL
1995	NULL
The	NULL
protein	NULL
product	NULL
of	NULL
the	NULL
c-fps/fes	NULL
(	NULL
c-fes	NULL
)	NULL
proto-oncogene	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
normal	NULL
development	NULL
of	NULL
myeloid	NULL
cells	NULL
(	NULL
macrophages	NULL
and	NULL
neutrophils	NULL
)	NULL
.	NULL

mRNA	NULL
for	NULL
c-fes	NULL
has	NULL
been	NULL
detected	NULL
exclusively	NULL
in	NULL
myeloid	NULL
cells	NULL
and	NULL
vascular	NULL
endothelial	NULL
cells	NULL
in	NULL
adult	NULL
mammals	NULL
.	NULL

Although	NULL
a	NULL
13-kilobase-pair	NULL
(	NULL
kb	NULL
)	NULL
human	NULL
c-fes	NULL
transgene	NULL
exhibits	NULL
high	NULL
levels	NULL
of	NULL
expression	NULL
in	NULL
mice	NULL
,	NULL
the	NULL
sequences	NULL
that	NULL
confer	NULL
myeloid-cell-specific	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
¢-fes	NULL
gene	NULL
have	NULL
not	NULL
been	NULL
defined	NULL
.	NULL

Transient-transfection	NULL
experiments	NULL
demonstrated	NULL
that	NULL
plasmids	NULL
containing	NULL
446	NULL
bp	NULL
of	NULL
c-fes	NULL
5	NULL
'	NULL
-flanking	NULL
sequences	NULL
linked	NULL
to	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
were	NULL
active	NULL
exclusively	NULL
in	NULL
myeloid	NULL
cells	NULL
.	NULL

No	NULL
other	NULL
DNA	NULL
elements	NULL
within	NULL
the	NULL
13-kb	NULL
human	NULL
c-fes	NULL
locus	NULL
contained	NULL
positive	NULL
cis-acting	NULL
elements	NULL
,	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
a	NULL
weakly	NULL
active	NULL
region	NULL
within	NULL
the	NULL
-flanking	NULL
sequences	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
assays	NULL
revealed	NULL
four	NULL
distinct	NULL
sites	NULL
that	NULL
bind	NULL
myeloid	NULL
nuclear	NULL
proteins	NULL
(	NULL
-408	NULL
to	NULL
-386	NULL
,	NULL
-293	NULL
to	NULL
-254	NULL
,	NULL
-76	NULL
to	NULL
-65	NULL
,	NULL
and	NULL
-34	NULL
to	NULL
+3	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
first	NULL
two	NULL
footprints	NULL
resided	NULL
in	NULL
sequences	NULL
that	NULL
were	NULL
largely	NULL
dispensable	NULL
for	NULL
transient	NULL
activity	NULL
.	NULL

Plasmids	NULL
containing	NULL
151	NULL
bp	NULL
of	NULL
5'-flanking	NULL
sequences	NULL
confer	NULL
myeloid-cell-specific	NULL
gene	NULL
expression	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
analyses	NULL
demonstrated	NULL
that	NULL
the	NULL
151-bp	NULL
region	NULL
contains	NULL
nuclear	NULL
protein	NULL
binding	NULL
sites	NULL
for	NULL
Sp1	NULL
,	NULL
PU.1	NULL
,	NULL
and/or	NULL
Elf-1	NULL
,	NULL
and	NULL
a	NULL
novel	NULL
factor	NULL
.	NULL

This	NULL
unidentified	NULL
factor	NULL
binds	NULL
immediately	NULL
3	NULL
'	NULL
of	NULL
the	NULL
PU.1/Elf-1	NULL
site	NULL
and	NULL
appears	NULL
to	NULL
be	NULL
myeloid	NULL
cell	NULL
specific	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
PU.1/Elf-1	NULL
site	NULL
or	NULL
the	NULL
3	NULL
'	NULL
site	NULL
(	NULL
FP4-3	NULL
'	NULL
)	NULL
within	NULL
the	NULL
context	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
resulted	NULL
in	NULL
substantially	NULL
reduced	NULL
activity	NULL
in	NULL
transient	NULL
transfections	NULL
.	NULL

Furthermore	NULL
,	NULL
transient-cotransfection	NULL
assays	NULL
demonstrated	NULL
that	NULL
PU.1	NULL
(	NULL
and	NULL
not	NULL
Elf-1	NULL
)	NULL
can	NULL
transactivate	NULL
the	NULL
c-fes	NULL
promoter	NULL
in	NULL
nonmyeloid	NULL
cell	NULL
lines	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
the	NULL
human	NULL
c-fes	NULL
gene	NULL
contains	NULL
a	NULL
strong	NULL
myeloid-cell-specific	NULL
promoter	NULL
that	NULL
is	NULL
regulated	NULL
by	NULL
Sp1	NULL
,	NULL
PU.1	NULL
,	NULL
and	NULL
a	NULL
novel	NULL
transcription	NULL
factor	NULL
.	NULL

During	NULL
mammalian	NULL
development	NULL
,	NULL
specific	NULL
cells	NULL
within	NULL
the	NULL
mesoderm	NULL
differentiate	NULL
into	NULL
pluripotent	NULL
hematopoietic	NULL
stem	NULL
cells	NULL
that	NULL
form	NULL
all	NULL
blood	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
lymphocytes	NULL
,	NULL
megakaryocytes	NULL
,	NULL
erythrocytes	NULL
,	NULL
granulocytes	NULL
,	NULL
and	NULL
monocytes	NULL
.	NULL

Proto-oncogenes	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
cellular	NULL
differentiation	NULL
.	NULL

Several	NULL
mammalian	NULL
proto-oncogenes	NULL
exhibit	NULL
restricted	NULL
patterns	NULL
of	NULL
expression	NULL
,	NULL
suggesting	NULL
that	NULL
their	NULL
transcription	NULL
is	NULL
tightly	NULL
controlled	NULL
and	NULL
that	NULL
they	NULL
encode	NULL
proteins	NULL
with	NULL
lineage-specific	NULL
functions	NULL
(	NULL
30	NULL
,	NULL
33	NULL
,	NULL
38	NULL
)	NULL
.	NULL

The	NULL
c-fps/fes	NULL
(	NULL
here-in	NULL
referred	NULL
to	NULL
as	NULL
c-fes	NULL
)	NULL
proto-oncogene	NULL
encodes	NULL
a	NULL
92-kDa	NULL
cy-toplasmic	NULL
protein-tyrosine	NULL
kinase	NULL
that	NULL
includes	NULL
a	NULL
Src	NULL
homology	NULL
2	NULL
domain	NULL
and	NULL
a	NULL
carboxyl-terminal	NULL
catalytic	NULL
domain	NULL
(	NULL
29	NULL
)	NULL
.	NULL

c-fes	NULL
is	NULL
distinct	NULL
from	NULL
members	NULL
of	NULL
the	NULL
Sre	NULL
family	NULL
of	NULL
tyrosine	NULL
kinases	NULL
in	NULL
that	NULL
it	NULL
lacks	NULL
a	NULL
negative	NULL
regulatory	NULL
tyrosine	NULL
phosphorylation	NULL
site	NULL
in	NULL
its	NULL
carboxyl-terminal	NULL
region	NULL
,	NULL
is	NULL
not	NULL
modified	NULL
by	NULL
N-terminal	NULL
myristylation	NULL
,	NULL
and	NULL
does	NULL
not	NULL
have	NULL
a	NULL
Sre	NULL
homology	NULL
3	NULL
domain	NULL
.	NULL

Previously	NULL
,	NULL
the	NULL
c-fes	NULL
protein	NULL
(	NULL
p92	NULL
)	NULL
had	NULL
been	NULL
detected	NULL
only	NULL
in	NULL
hematopoietic	NULL
cells	NULL
in	NULL
adult	NULL
mammals	NULL
and	NULL
birds	NULL
,	NULL
predominantly	NULL
in	NULL
differentiated	NULL
neutrophils	NULL
and	NULL
macrophages	NULL
and	NULL
their	NULL
precursors	NULL
(	NULL
7	NULL
,	NULL
17	NULL
,	NULL
19	NULL
,	NULL
29	NULL
,	NULL
32	NULL
)	NULL
.	NULL

However	NULL
,	NULL
more	NULL
recent	NULL
experiments	NULL
have	NULL
shown	NULL
that	NULL
c-fes	NULL
is	NULL
also	NULL
expressed	NULL
in	NULL
vascular	NULL
endothelial	NULL
cells	NULL
and	NULL
several	NULL
rapidly	NULL
proliferating	NULL
embryonic	NULL
tissues	NULL
(	NULL
3	NULL
,	NULL
10	NULL
)	NULL
.	NULL

A	NULL
requirement	NULL
for	NULL
p92	NULL
``	NULL
in	NULL
myeloid-cell	NULL
(	NULL
monocyte	NULL
and	NULL
neutrophil	NULL
)	NULL
development	NULL
has	NULL
been	NULL
suggested	NULL
by	NULL
a	NULL
number	NULL
of	NULL
experiments	NULL
.	NULL

Introduction	NULL
of	NULL
a	NULL
c-fes	NULL
genomic	NULL
clone	NULL
into	NULL
leuke-	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
University	NULL
of	NULL
Chicago	NULL
,	NULL
5841	NULL
S.	NULL
Maryland	NULL
Ave.	NULL
,	NULL
MC	NULL
1028	NULL
,	NULL
Chicago	NULL
,	NULL
IL	NULL
60637	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
312	NULL
)	NULL
702-4721	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
312	NULL
)	NULL
702-2681	NULL
.	NULL

1676	NULL
mic	NULL
(	NULL
K562	NULL
)	NULL
cells	NULL
induces	NULL
them	NULL
to	NULL
undergo	NULL
terminal	NULL
myeloid	NULL
differentiation	NULL
(	NULL
40	NULL
)	NULL
.	NULL

c-fes	NULL
kinase	NULL
activity	NULL
increases	NULL
following	NULL
treatment	NULL
of	NULL
HL60	NULL
cells	NULL
with	NULL
the	NULL
granulocyte	NULL
inducer	NULL
retinoic	NULL
acid	NULL
and	NULL
monocyte	NULL
inducers	NULL
such	NULL
as	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
(	NULL
32	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
inhibition	NULL
of	NULL
c-fes	NULL
expression	NULL
with	NULL
antisense	NULL
oligonucleotides	NULL
in	NULL
HL60	NULL
cells	NULL
before	NULL
induction	NULL
with	NULL
retinoic	NULL
acid	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
programmed	NULL
cell	NULL
death	NULL
(	NULL
8	NULL
,	NULL
20	NULL
)	NULL
.	NULL

Granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
and	NULL
interleukin-3	NULL
are	NULL
potent	NULL
hematopoietic	NULL
growth	NULL
factors	NULL
which	NULL
stimulate	NULL
the	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
various	NULL
hematopoietic	NULL
cells	NULL
,	NULL
including	NULL
granulocyte	NULL
and	NULL
macrophage	NULL
progenitor	NULL
cells	NULL
.	NULL

One	NULL
study	NULL
reported	NULL
a	NULL
direct	NULL
association	NULL
between	NULL
p92	NULL
``	NULL
and	NULL
the	NULL
common	NULL
B	NULL
chain	NULL
of	NULL
the	NULL
human	NULL
interleukin-3	NULL
and	NULL
GM-CSF	NULL
receptors	NULL
that	NULL
is	NULL
catalytically	NULL
activated	NULL
upon	NULL
ligand	NULL
binding	NULL
(	NULL
13	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
that	NULL
p92	NULL
``	NULL
is	NULL
involved	NULL
in	NULL
regulating	NULL
proliferation	NULL
and	NULL
differentiation	NULL
during	NULL
myelopoiesis	NULL
.	NULL

It	NULL
may	NULL
also	NULL
be	NULL
essential	NULL
for	NULL
the	NULL
survival	NULL
of	NULL
myeloid	NULL
cells	NULL
during	NULL
differentiation	NULL
.	NULL

A	NULL
13-kilobase-pair	NULL
(	NULL
kb	NULL
)	NULL
c-fes	NULL
human	NULL
genomic	NULL
construct	NULL
is	NULL
expressed	NULL
in	NULL
transgenic	NULL
mice	NULL
in	NULL
a	NULL
tissue-specific	NULL
manner	NULL
and	NULL
at	NULL
levels	NULL
comparable	NULL
to	NULL
that	NULL
of	NULL
the	NULL
endogenous	NULL
murine	NULL
gene	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
transgene	NULL
in	NULL
mouse	NULL
bone	NULL
marrow	NULL
is	NULL
independent	NULL
of	NULL
the	NULL
integration	NULL
site	NULL
and	NULL
proportional	NULL
to	NULL
the	NULL
transgene	NULL
copy	NULL
number	NULL
.	NULL

Remarkably	NULL
,	NULL
this	NULL
13-kb	NULL
genomic	NULL
fragment	NULL
includes	NULL
only	NULL
446	NULL
bp	NULL
of	NULL
5'-	NULL
and	NULL
1.4	NULL
kb	NULL
of	NULL
3'-flanking	NULL
sequences	NULL
and	NULL
must	NULL
,	NULL
by	NULL
definition	NULL
,	NULL
include	NULL
all	NULL
cis-acting	NULL
DNA	NULL
elements	NULL
required	NULL
for	NULL
high	NULL
levels	NULL
of	NULL
myeloid-cell-specific	NULL
expression	NULL
.	NULL

To	NULL
locate	NULL
where	NULL
these	NULL
cis-acting	NULL
elements	NULL
reside	NULL
and	NULL
to	NULL
identify	NULL
trans-acting	NULL
factors	NULL
which	NULL
bind	NULL
to	NULL
them	NULL
,	NULL
we	NULL
have	NULL
studied	NULL
the	NULL
expression	NULL
of	NULL
various	NULL
c-fes	NULL
DNA	NULL
elements	NULL
linked	NULL
to	NULL
a	NULL
reporter	NULL
gene	NULL
in	NULL
transient-transfection	NULL
Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
assays	NULL
in	NULL
two	NULL
myeloid	NULL
cell	NULL
lines	NULL
.	NULL

We	NULL
report	NULL
that	NULL
the	NULL
5'-flanking	NULL
151	NULL
bp	NULL
of	NULL
c-fes	NULL
contain	NULL
a	NULL
strong	NULL
myeloid-cell-specific	NULL
promoter	NULL
.	NULL

This	NULL
promoter	NULL
contains	NULL
functionally	NULL
important	NULL
binding	NULL
sites	NULL
for	NULL
Sp1	NULL
,	NULL
PU.1	NULL
,	NULL
and	NULL
a	NULL
novel	NULL
transcription	NULL
factor	NULL
.	NULL

Also	NULL
,	NULL
PU.1	NULL
transactivates	NULL
the	NULL
promoter	NULL
in	NULL
nonmyeloid	NULL
cell	NULL
lines	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
RNase	NULL
protection	NULL
assay	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
the	NULL
following	NULL
human-derived	NULL
cell	NULL
lines	NULL
:	NULL
Hela	NULL
,	NULL
Jurkat	NULL
,	NULL
K562	NULL
,	NULL
U937	NULL
,	NULL
HL60	NULL
,	NULL
and	NULL
THP-1	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
separate	NULL
flask	NULL
of	NULL
U937	NULL
cells	NULL
was	NULL
treated	NULL
with	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
at	NULL
54	NULL
nM	NULL
for	NULL
16	NULL
h	NULL
prior	NULL
to	NULL
RNA	NULL
isolation	NULL
.	NULL

All	NULL
cell	NULL
lines	NULL
were	NULL
passaged	NULL
1:3	NULL
24	NULL
h	NULL
prior	NULL
to	NULL
RNA	NULL
extraction	NULL
to	NULL
ensure	NULL
that	NULL
cells	NULL
were	NULL
healthy	NULL
.	NULL

The	NULL
TRIzol	NULL
reagent	NULL
(	NULL
Gibco/BRL	NULL
)	NULL
for	NULL
RNA	NULL
purification	NULL
was	NULL
used	NULL
as	NULL
specified	NULL
by	NULL
the	NULL
manufacturer	NULL
except	NULL
that	NULL
two	NULL
rounds	NULL
of	NULL
extraction	NULL
were	NULL
performed	NULL
to	NULL
completely	NULL
remove	NULL
contaminating	NULL
genomic	NULL
DNA	NULL
.	NULL

Antisense	NULL
¢-fes	NULL
and	NULL
B-actin	NULL
RNA	NULL
probes	NULL
were	NULL
generated	NULL
by	NULL
in	NULL
vitro	NULL
transcription	NULL
with	NULL
T7	NULL
polymerase	NULL
and	NULL
linearized	NULL
plasmids	NULL
.	NULL

The	NULL
c-fes	NULL
probe	NULL
corresponds	NULL
to	NULL
genomic	NULL
DNA	NULL
positions	NULL
11273	NULL
through	NULL
11645	NULL
(	NULL
GenBank	NULL
accession	NULL
number	NULL
X06292	NULL
)	NULL
and	NULL
protects	NULL
273	NULL
bp	NULL
of	NULL
exon	NULL
19	NULL
.	NULL

The	NULL
B-actin	NULL
construct	NULL
(	NULL
Ambion	NULL
)	NULL
produces	NULL
a	NULL
189-bp	NULL
transcript	NULL
and	NULL
protects	NULL
a	NULL
127-bp	NULL
fragment	NULL
.	NULL

Analysis	NULL
was	NULL
performed	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

Plasmid	NULL
construction	NULL
.	NULL

Plasmid	NULL
pSVBR91	NULL
contains	NULL
the	NULL
13-kb	NULL
EcoRI	NULL
human	NULL
c-fes	NULL
genomic	NULL
locus	NULL
and	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
A.	NULL
J.	NULL
M.	NULL
Rocbrock	NULL
.	NULL

Plasmid	NULL
p446	NULL
contains	NULL
the	NULL
c-fes	NULL
promoter	NULL
(	NULL
bp	NULL
-446	NULL
to	NULL
+71	NULL
)	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
firefly	NULL
luciferase	NULL
reporter	NULL
pGL2-basic	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

The	NULL
517-bp	NULL
EcoRI-KpnI	NULL
fragment	NULL
from	NULL
pSVBR91	NULL
was	NULL
subcloned	NULL
into	NULL
Smel-Kpnl-digested	NULL
pGL2	NULL
.	NULL

A	NULL
series	NULL
of	NULL
5	NULL
``	NULL
deletions	NULL
were	NULL
made	NULL
by	NULL
subcloning	NULL
a	NULL
BssHII-KprI	NULL
fragment	NULL
(	NULL
yielding	NULL
p366	NULL
)	NULL
,	NULL
an	NULL
Eagl-KpnI	NULL
fragment	NULL
(	NULL
yielding	NULL
p151	NULL
)	NULL
,	NULL
and	NULL
a	NULL
Smel-KpnI	NULL
fragment	NULL
(	NULL
yielding	NULL
p31	NULL
)	NULL
into	NULL
pGL2	NULL
.	NULL

The	NULL
p251	NULL
and	NULL
p99	NULL
constructs	NULL
were	NULL
generated	NULL
by	NULL
subcloning	NULL
PCR-amplified	NULL
products	NULL
into	NULL
pGL2-basic	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
following	NULL
oligonucleotides	NULL
:	NULL
for	NULL
PU.1	NULL
,	NULL
5-GGGGCCTGGGCCAACTGA	NULL
AACCGCGGGAGCACCGGGCGCGGAATCAGGAACTGGCCGGGG	NULL
TCCGCACCGGGCCTGAGTCGGTCCGGTAC-3	NULL
'	NULL
,	NULL
and	NULL
for	NULL
FP4-3	NULL
'	NULL
,	NULL
5'-GGAG	NULL
GAAGCGCGCCACCAGGAACTGGCC-3	NULL
'	NULL
.	NULL

The	NULL
underlined	NULL
sequences	NULL
indicate	NULL
the	NULL
nucleotides	NULL
that	NULL
were	NULL
changed	NULL
from	NULL
wild-type	NULL
sequences	NULL
.	NULL

A	NULL
plasmid	NULL
containing	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
putative	NULL
Ets	NULL
site	NULL
was	NULL
made	NULL
by	NULL
first	NULL
subcloning	NULL
a	NULL
construct	NULL
harboring	NULL
an	NULL
Ets	NULL
site	NULL
mutation	NULL
in	NULL
51	NULL
bp	NULL
of	NULL
5'-flanking	NULL
sequences	NULL
and	NULL
then	NULL
cloning	NULL
an	NULL
EcoRI-Smel	NULL
partial	NULL
restriction	NULL
fragment	NULL
upstream	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
potential	NULL
AP-1	NULL
site	NULL
were	NULL
generated	NULL
by	NULL
PCRs	NULL
with	NULL
mutant	NULL
primers	NULL
.	NULL

Constructs	NULL
containing	NULL
downstream	NULL
sequences	NULL
were	NULL
generated	NULL
by	NULL
subcloning	NULL
six	NULL
distinct	NULL
Secl	NULL
fragments	NULL
into	NULL
the	NULL
pGL2	NULL
promoter	NULL
plasmid	NULL
that	NULL
contains	NULL
a	NULL
simian	NULL
virus	NULL
40	NULL
(	NULL
SV40	NULL
)	NULL
promoter	NULL
5	NULL
``	NULL
of	NULL
the	NULL
luciferase	NULL
gene	NULL
or	NULL
four	NULL
distinct	NULL
BamHI	NULL
fragments	NULL
into	NULL
a	NULL
3	NULL
'	NULL
site	NULL
of	NULL
p446	NULL
.	NULL

A	NULL
1.4-kb	NULL
Nsil-EcoRI	NULL
fragment	NULL
from	NULL
the	NULL
c-fes	NULL
genomic	NULL
construct	NULL
which	NULL
contains	NULL
3'-flanking	NULL
sequences	NULL
was	NULL
subcloned	NULL
into	NULL
both	NULL
the	NULL
pGL2	NULL
promoter	NULL
and	NULL
p446	NULL
.	NULL

Reference	NULL
plasmids	NULL
for	NULL
transient	NULL
transfections	NULL
consisted	NULL
of	NULL
luciferase	NULL
coding	NULL
sequences	NULL
with	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
promoter	NULL
and	NULL
growth	NULL
hormone	NULL
(	NULL
GH	NULL
)	NULL
with	NULL
the	NULL
cytomegalovirus	NULL
promoter	NULL
.	NULL

All	NULL
plasmids	NULL
were	NULL
verified	NULL
by	NULL
dideoxy-DNA	NULL
sequencing	NULL
.	NULL

Cell	NULL
culture	NULL
and	NULL
transient-expression	NULL
analysis	NULL
.	NULL

Both	NULL
U937	NULL
and	NULL
K562	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
penicillin	NULL
,	NULL
streptomycin	NULL
,	NULL
and	NULL
glutamine	NULL
.	NULL

Cos	NULL
and	NULL
HeLa	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
Dulbecco	NULL
modified	NULL
Eagle	NULL
medium	NULL
containing	NULL
the	NULL
same	NULL
additives	NULL
.	NULL

Approximately	NULL
24	NULL
h	NULL
prior	NULL
to	NULL
electroporation	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
split	NULL
1:3	NULL
with	NULL
fresh	NULL
medium	NULL
.	NULL

The	NULL
following	NULL
day	NULL
,	NULL
U937	NULL
and	NULL
K562	NULL
cells	NULL
were	NULL
electroporated	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Cos	NULL
and	NULL
HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
Lipofectin	NULL
reagent	NULL
(	NULL
Gibco/BRL	NULL
)	NULL
.	NULL

Duplicate	NULL
transfections	NULL
were	NULL
performed	NULL
by	NULL
combining	NULL
the	NULL
cells	NULL
,	NULL
100	NULL
pg	NULL
of	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
,	NULL
and	NULL
2	NULL
g	NULL
of	NULL
the	NULL
GH	NULL
reference	NULL
plasmid	NULL
,	NULL
peDNA-GH	NULL
,	NULL
in	NULL
electroporation	NULL
cuvettes	NULL
.	NULL

At	NULL
the	NULL
time	NULL
of	NULL
plating	NULL
,	NULL
all	NULL
of	NULL
the	NULL
U937	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
54	NULL
nM	NULL
PMA	NULL
to	NULL
increase	NULL
the	NULL
transfection	NULL
efficiency	NULL
as	NULL
reported	NULL
previously	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Cos	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
16	NULL
ug	NULL
of	NULL
peDNA3	NULL
expression	NULL
plasmid	NULL
(	NULL
Invitrogen	NULL
)	NULL
containing	NULL
PU.1	NULL
or	NULL
Elf-1	NULL
,	NULL
4	NULL
pg	NULL
of	NULL
test	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
,	NULL
and	NULL
2	NULL
ag	NULL
of	NULL
the	NULL
GH	NULL
reference	NULL
plasmid	NULL
.	NULL

After	NULL
13	NULL
h	NULL
(	NULL
for	NULL
U937	NULL
and	NULL
K562	NULL
cells	NULL
)	NULL
or	NULL
48	NULL
h	NULL
(	NULL
for	NULL
Cos	NULL
and	NULL
HeLa	NULL
cells	NULL
)	NULL
of	NULL
culture	NULL
at	NULL
37°C	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
protein	NULL
content	NULL
,	NULL
secreted	NULL
GH	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
.	NULL

Luciferase	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
equivalent	NULL
amounts	NULL
of	NULL
protein	NULL
obtained	NULL
from	NULL
all	NULL
cell	NULL
extracts	NULL
.	NULL

GH	NULL
activity	NULL
was	NULL
measured	NULL
on	NULL
transfected-cell	NULL
medium	NULL
supernatants	NULL
by	NULL
radioimmunoassay	NULL
as	NULL
specified	NULL
by	NULL
Nichols	NULL
Institute	NULL
.	NULL

As	NULL
a	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
,	NULL
plasmid	NULL
expression	NULL
was	NULL
quantitated	NULL
as	NULL
relative	NULL
light	NULL
units	NULL
normalized	NULL
to	NULL
nanograms	NULL
of	NULL
GH	NULL
secreted	NULL
.	NULL

All	NULL
transfections	NULL
were	NULL
performed	NULL
at	NULL
least	NULL
three	NULL
times	NULL
to	NULL
ensure	NULL
reproducibility	NULL
.	NULL

Nuclear	NULL
extracts	NULL
and	NULL
EMSAs	NULL
.	NULL

Nuclear	NULL
extracts	NULL
of	NULL
U937	NULL
cells	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
5	NULL
)	NULL
,	NULL
assayed	NULL
for	NULL
protein	NULL
content	NULL
(	NULL
Bio-Rad	NULL
)	NULL
,	NULL
and	NULL
used	NULL
to	NULL
identify	NULL
protein	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
5	NULL
'	NULL
region	NULL
of	NULL
the	NULL
c-fes	NULL
gene	NULL
between	NULL
positions	NULL
-446	NULL
and	NULL
+71	NULL
relative	NULL
to	NULL
the	NULL
primary	NULL
transcriptional	NULL
start	NULL
site	NULL
.	NULL

Because	NULL
of	NULL
its	NULL
length	NULL
,	NULL
this	NULL
fragment	NULL
was	NULL
digested	NULL
with	NULL
Eeg	NULL
!	NULL

(	NULL
which	NULL
cuts	NULL
at	NULL
-151	NULL
)	NULL
,	NULL
thus	NULL
generating	NULL
two	NULL
probes	NULL
containing	NULL
294	NULL
and	NULL
223	NULL
bp	NULL
of	NULL
DNA	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
assays	NULL
were	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
in	NULL
reference	NULL
6	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
were	NULL
performed	NULL
by	NULL
incubating	NULL
10	NULL
ag	NULL
of	NULL
nuclear	NULL
extract	NULL
(	NULL
2	NULL
)	NULL
with	NULL
10,000	NULL
dpm	NULL
of	NULL
each	NULL
radiolabeled	NULL
probe	NULL
as	NULL
REGULATION	NULL
OF	NULL
c-fes	NULL
BY	NULL
A	NULL
NOVEL	NULL
TRANSCRIPTION	NULL
FACTOR	NULL
1677	NULL
described	NULL
previously	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
radiolabeled	NULL
oligonucleotide	NULL
probes	NULL
were	NULL
incubated	NULL
with	NULL
in	NULL
vitro-translated	NULL
proteins	NULL
prepared	NULL
with	NULL
T7-coupled	NULL
reticulocyte	NULL
lysates	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Reactions	NULL
were	NULL
performed	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4°C	NULL
or	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
following	NULL
oligonucleotides	NULL
were	NULL
utilized	NULL
:	NULL
c-fes	NULL
Sp1	NULL
(	NULL
-102	NULL
to	NULL
-46	NULL
)	NULL
,	NULL
5'-age	NULL
CCGCCCCGGGG-3	NULL
'	NULL
;	NULL
Spl	NULL
.	NULL

consensus	NULL
,	NULL
5'-gateCCTGGCTAAAGGGGCGGG	NULL
GCTTGGCCAGCC-3	NULL
'	NULL
;	NULL
PU.1/Elf-1	NULL
binding	NULL
site	NULL
,	NULL
PU.1	NULL
(	NULL
-32	NULL
to	NULL
-1	NULL
)	NULL
,	NULL
5'-gatcAAA	NULL
CCGCGGGAGGAGGAAGCGCGGAATCAGGA-3	NULL
'	NULL
;	NULL
PU.1/FPA-3	NULL
'	NULL
(	NULL
-32	NULL
to	NULL
+14	NULL
)	NULL
,	NULL
-	NULL
5'-agcttAAACCGCGGGAGGAGGAAGCGCGGAATCAGGAACTG	NULL
GCCGGGGTCC-3	NULL
'	NULL
;	NULL
and	NULL
the	NULL
PU.1	NULL
consensus	NULL
from	NULL
the	NULL
SV40	NULL
promoter	NULL
(	NULL
26	NULL
)	NULL
.	NULL

The	NULL
mutated	NULL
PU.1	NULL
site	NULL
in	NULL
the	NULL
PU.1	NULL
oligonucleotide	NULL
(	NULL
-32	NULL
to	NULL
-1	NULL
)	NULL
and	NULL
the	NULL
SV40	NULL
oligonucleotide	NULL
are	NULL
listed	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
and	NULL
8	NULL
.	NULL

The	NULL
sequences	NULL
utilized	NULL
to	NULL
analyze	NULL
the	NULL
flanking	NULL
site	NULL
binding	NULL
requirements	NULL
were	NULL
made	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
c-fes	NULL
oligonucleotide	NULL
PU.1/FP4-3	NULL
'	NULL
(	NULL
-32	NULL
to	NULL
+14	NULL
)	NULL
and	NULL
are	NULL
as	NULL
follows	NULL
:	NULL
mutation	NULL
1	NULL
(	NULL
mut1	NULL
)	NULL
,	NULL
5'-gettAAACCGCGGGAGGAGGAAGCGCGCCACCAGGAACTGGCCGG	NULL
GGTCC	NULL
C-3	NULL
'	NULL
;	NULL
mut2	NULL
,	NULL
5'-agcttAAACCCGGGAGGAGGAAGCGCGCCACGG	NULL
GGAACTGGCCGGGGTCC-3	NULL
'	NULL
;	NULL
and	NULL
mut3	NULL
,	NULL
5'-agcttAAACCGCGGGAGGAG	NULL
GAAGCGCCCTAATTAAGGCTGGCCGGGGTCC-3	NULL
'	NULL
.	NULL

The	NULL
underlined	NULL
sequences	NULL
represent	NULL
mutated	NULL
bases	NULL
.	NULL

The	NULL
lowercase	NULL
letters	NULL
indicate	NULL
the	NULL
sequences	NULL
used	NULL
for	NULL
subcloning	NULL
purposes	NULL
.	NULL

The	NULL
consensus	NULL
AP-1	NULL
site	NULL
is	NULL
from	NULL
the	NULL
metallothionein	NULL
promoter	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
rabbit	NULL
polyclonal	NULL
antisera	NULL
specific	NULL
for	NULL
human	NULL
Spl	NULL
,	NULL
murine	NULL
PU.1	NULL
,	NULL
human	NULL
pan-fos	NULL
,	NULL
and	NULL
murine	NULL
pan-jur	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
A	NULL
second	NULL
polyclonal	NULL
antibody	NULL
specific	NULL
for	NULL
full-length	NULL
PU.1	NULL
was	NULL
a	NULL
gift	NULL
of	NULL
David	NULL
Kabat	NULL
.	NULL

A	NULL
monoclonal	NULL
antibody	NULL
specific	NULL
for	NULL
Elf-1	NULL
was	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
Jeff	NULL
Leiden	NULL
.	NULL

Supershift	NULL
and/or	NULL
blocking	NULL
reactions	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
above	NULL
for	NULL
EMSAs	NULL
.	NULL

RESULTS	NULL
e-fes	NULL
is	NULL
transcribed	NULL
in	NULL
human	NULL
myeloid	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
the	NULL
human	NULL
genome	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
fur	NULL
,	NULL
a	NULL
gene	NULL
encoding	NULL
a	NULL
transmem-brane	NULL
protein	NULL
with	NULL
receptor-like	NULL
features	NULL
,	NULL
is	NULL
located	NULL
approximately	NULL
1	NULL
kb	NULL
upstream	NULL
of	NULL
the	NULL
first	NULL
exon	NULL
of	NULL
c-fes	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
fur	NULL
and	NULL
c-fes	NULL
are	NULL
expressed	NULL
in	NULL
distinct	NULL
tissues	NULL
.	NULL

The	NULL
13-kb	NULL
human	NULL
c-fes	NULL
genomic	NULL
fragment	NULL
,	NULL
which	NULL
displays	NULL
high	NULL
levels	NULL
of	NULL
tissue-specific	NULL
expression	NULL
in	NULL
transgenic	NULL
mice	NULL
,	NULL
contains	NULL
446	NULL
bp	NULL
of	NULL
5'-flanking	NULL
sequences	NULL
and	NULL
1.4	NULL
kb	NULL
of	NULL
3'-flanking	NULL
sequences	NULL
.	NULL

The	NULL
¢-fes	NULL
locus	NULL
includes	NULL
19	NULL
exons	NULL
,	NULL
one	NULL
DNase	NULL
I-hypersensitive	NULL
site	NULL
located	NULL
5	NULL
'	NULL
of	NULL
the	NULL
first	NULL
exon	NULL
,	NULL
and	NULL
two	NULL
sites	NULL
located	NULL
between	NULL
exons	NULL
3	NULL
and	NULL
4	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
of	NULL
p92	NULL
``	NULL
indicated	NULL
that	NULL
it	NULL
is	NULL
preferentially	NULL
expressed	NULL
in	NULL
myeloid	NULL
cells	NULL
in	NULL
adults	NULL
.	NULL

To	NULL
confirm	NULL
and	NULL
extend	NULL
these	NULL
results	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
relative	NULL
levels	NULL
of	NULL
c-fes	NULL
expression	NULL
in	NULL
various	NULL
human	NULL
cell	NULL
lines	NULL
by	NULL
RNase	NULL
protection	NULL
analyses	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

RNA	NULL
was	NULL
isolated	NULL
from	NULL
four	NULL
myeloid	NULL
cell	NULL
lines	NULL
(	NULL
K562	NULL
,	NULL
U937	NULL
,	NULL
HL60	NULL
,	NULL
and	NULL
THP-1	NULL
)	NULL
,	NULL
an	NULL
epithelial	NULL
carcinoma	NULL
cell	NULL
line	NULL
(	NULL
HeLa	NULL
)	NULL
,	NULL
and	NULL
a	NULL
T-cell	NULL
line	NULL
(	NULL
Jurkat	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
c-fes	NULL
mRNA	NULL
was	NULL
detected	NULL
in	NULL
U937	NULL
,	NULL
HL60	NULL
,	NULL
and	NULL
THP-1	NULL
cells	NULL
but	NULL
was	NULL
not	NULL
detectable	NULL
in	NULL
either	NULL
the	NULL
T	NULL
cells	NULL
or	NULL
epithelial	NULL
cells	NULL
.	NULL

K562	NULL
cells	NULL
were	NULL
established	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
and	NULL
exhibit	NULL
both	NULL
erythrocytic	NULL
and	NULL
early	NULL
monocytic	NULL
characteristics	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Experiments	NULL
involving	NULL
gene	NULL
transfer	NULL
into	NULL
K562	NULL
cells	NULL
with	NULL
the	NULL
13-kb	NULL
c-fes	NULL
human	NULL
genomic	NULL
clone	NULL
resulted	NULL
in	NULL
high	NULL
levels	NULL
of	NULL
c-fes	NULL
mRNA	NULL
and	NULL
kinase	NULL
activity	NULL
and	NULL
subsequent	NULL
myeloid	NULL
differentiation	NULL
(	NULL
40	NULL
)	NULL
.	NULL

We	NULL
did	NULL
not	NULL
detect	NULL
any	NULL
endogenous	NULL
c-fes	NULL
mRNA	NULL
in	NULL
K562	NULL
cells	NULL
by	NULL
RNase	NULL
protection	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
but	NULL
could	NULL
detect	NULL
low	NULL
levels	NULL
by	NULL
reverse	NULL
transcription-PCR	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

c-fes	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
have	NULL
also	NULL
been	NULL
reported	NULL
to	NULL
increase	NULL
as	NULL
monocytes	NULL
and	NULL
granulocytes	NULL
mature	NULL
.	NULL

Treatment	NULL
of	NULL
U937	NULL
cells	NULL
with	NULL
phorbol	NULL
esters	NULL
induces	NULL
terminal	NULL
monocytic	NULL
differentiation	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
stimulated	NULL
U937	NULL
cells	NULL
with	NULL
PMA	NULL
in	NULL
order	NULL
to	NULL
test	NULL
the	NULL
hypothesis	NULL
that	NULL
this	NULL
would	NULL
induce	NULL
c-fes	NULL
transcription	NULL
.	NULL

However	NULL
,	NULL
PMA	NULL
treatment	NULL
for	NULL
16	NULL
h	NULL
decreased	NULL
mRNA	NULL
levels	NULL
in	NULL
U937	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

The	NULL
lower	NULL
panel	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
showing	NULL
hybridiza-tion	NULL
to	NULL
a	NULL
B-actin	NULL
probe	NULL
,	NULL
demonstrates	NULL
that	NULL
similar	NULL
amounts	NULL
of	NULL
RNA	NULL
were	NULL
analyzed	NULL
in	NULL
each	NULL
sample	NULL
.	NULL

Functional	NULL
domains	NULL
within	NULL
the	NULL
c-fes	NULL
gene	NULL
.	NULL

Transient	NULL
transfections	NULL
into	NULL
myeloid	NULL
cells	NULL
by	NULL
electroporation	NULL
were	NULL
conducted	NULL
to	NULL
identify	NULL
cis-acting	NULL
sites	NULL
within	NULL
the	NULL
13-kb	NULL
c-fes	NULL
locus	NULL
.	NULL

Initially	NULL
,	NULL
we	NULL
transfected	NULL
a	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
containing	NULL
bases	NULL
1678	NULL
HEYDEMANN	NULL
ET	NULL
AL	NULL
.	NULL

A.	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

TGA	NULL
3	NULL
'	NULL
fur	NULL
exon	NULL
E	NULL
I	NULL
l	NULL
E	NULL
HS	NULL
HS	NULL
+	NULL
ate	NULL
W	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
®	NULL
-l	NULL
&	NULL
TC	NULL
c-fes	NULL
,	NULL
273	NULL
bp	NULL
B-actin,127	NULL
bp	NULL
-	NULL
&	NULL
678910	NULL
Jurkat	NULL
K562	NULL
11	NULL
121314151617	NULL
18	NULL
19	NULL
U937	NULL
PMA-U937	NULL
PMA+	NULL
HL6O	NULL
Yeast	NULL
RNA	NULL
THP-1	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
the	NULL
human	NULL
c-fes	NULL
gene	NULL
.	NULL

The	NULL
19	NULL
exons	NULL
are	NULL
indicated	NULL
with	NULL
coding	NULL
regions	NULL
(	NULL
filled	NULL
boxes	NULL
)	NULL
and	NULL
noncoding	NULL
sequences	NULL
(	NULL
open	NULL
boxes	NULL
)	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
translational	NULL
initiation	NULL
and	NULL
termination	NULL
codons	NULL
and	NULL
DNase	NULL
I-hypersensitive	NULL
sites	NULL
(	NULL
HS	NULL
)	NULL
are	NULL
shown	NULL
.	NULL

The	NULL
3	NULL
'	NULL
end	NULL
of	NULL
fur	NULL
is	NULL
less	NULL
than	NULL
1.1	NULL
kb	NULL
upstream	NULL
of	NULL
exon	NULL
1	NULL
of	NULL
c-fes	NULL
.	NULL

(	NULL
B	NULL
)	NULL
c-fes	NULL
mRNA	NULL
production	NULL
in	NULL
human	NULL
cell	NULL
lines	NULL
.	NULL

Twenty-five	NULL
micrograms	NULL
of	NULL
total	NULL
RNA	NULL
was	NULL
hybridized	NULL
to	NULL
a	NULL
372-bp	NULL
c-fes	NULL
riboprobe	NULL
and	NULL
a	NULL
189-bp	NULL
B-actin	NULL
riboprobe	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
273-bp	NULL
c-fes-	NULL
and	NULL
127-bp	NULL
B-actin-protected	NULL
fragments	NULL
are	NULL
indicated	NULL
.	NULL

Twenty-five	NULL
micrograms	NULL
of	NULL
yeast	NULL
tRNA	NULL
was	NULL
included	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

Autoradiograms	NULL
were	NULL
scanned	NULL
with	NULL
an	NULL
Agfa	NULL
Arcus	NULL
Plus	NULL
scanner	NULL
into	NULL
a	NULL
Macintosh	NULL
Quadra	NULL
700	NULL
computer	NULL
with	NULL
Adobe	NULL
Photoshop	NULL
software	NULL
and	NULL
were	NULL
printed	NULL
on	NULL
a	NULL
Rasterops	NULL
CorrectPrint	NULL
300	NULL
printer	NULL
.	NULL

-446	NULL
to	NULL
+71	NULL
of	NULL
c-fes	NULL
into	NULL
U937	NULL
cells	NULL
.	NULL

This	NULL
plasmid	NULL
(	NULL
called	NULL
p446	NULL
)	NULL
increased	NULL
luciferase	NULL
activity	NULL
125,000	NULL
times	NULL
over	NULL
that	NULL
of	NULL
the	NULL
plasmid	NULL
pGL2-basic	NULL
negative	NULL
control	NULL
,	NULL
which	NULL
is	NULL
expressed	NULL
at	NULL
very	NULL
low	NULL
levels	NULL
in	NULL
U937	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
activity	NULL
obtained	NULL
with	NULL
the	NULL
c-fes	NULL
p446	NULL
reporter	NULL
plasmid	NULL
was	NULL
25	NULL
%	NULL
of	NULL
that	NULL
obtained	NULL
with	NULL
the	NULL
RSV-luciferase	NULL
positive	NULL
control	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

The	NULL
human	NULL
c-fes	NULL
promoter	NULL
contains	NULL
a	NULL
CpG	NULL
island	NULL
and	NULL
no	NULL
TATA	NULL
element	NULL
;	NULL
multiple	NULL
transcription	NULL
start	NULL
sites	NULL
have	NULL
been	NULL
determined	NULL
by	NULL
primer	NULL
extension	NULL
analysis	NULL
of	NULL
U937	NULL
and	NULL
HL60	NULL
mRNA	NULL
(	NULL
1	NULL
)	NULL
.	NULL

c-fes	NULL
transcripts	NULL
initiate	NULL
at	NULL
multiple	NULL
sites	NULL
within	NULL
exon	NULL
1	NULL
,	NULL
and	NULL
the	NULL
primary	NULL
site	NULL
corresponds	NULL
to	NULL
the	NULL
first	NULL
nucleotide	NULL
of	NULL
published	NULL
cDNA	NULL
sequences	NULL
(	NULL
1	NULL
)	NULL
.	NULL

One	NULL
additional	NULL
cap	NULL
site	NULL
is	NULL
located	NULL
at	NULL
the	NULL
5	NULL
'	NULL
border	NULL
of	NULL
exon	NULL
2	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
the	NULL
first	NULL
intron	NULL
serves	NULL
as	NULL
a	NULL
second	NULL
promoter	NULL
,	NULL
we	NULL
linked	NULL
DNA	NULL
sequences	NULL
from	NULL
this	NULL
region	NULL
to	NULL
luciferase	NULL
coding	NULL
sequences	NULL
and	NULL
transfected	NULL
this	NULL
construct	NULL
into	NULL
U937	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
high	NULL
levels	NULL
of	NULL
expression	NULL
noted	NULL
for	NULL
the	NULL
sequences	NULL
5	NULL
'	NULL
to	NULL
exon	NULL
1	NULL
,	NULL
sequences	NULL
within	NULL
the	NULL
first	NULL
intron	NULL
contain	NULL
no	NULL
transcriptional	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
other	NULL
positive	NULL
,	NULL
cis-acting	NULL
elements	NULL
for	NULL
transient	NULL
c-fes	NULL
expression	NULL
exist	NULL
within	NULL
the	NULL
13-kb	NULL
human	NULL
genomic	NULL
locus	NULL
(	NULL
in	NULL
particular	NULL
the	NULL
third	NULL
intron	NULL
,	NULL
where	NULL
two	NULL
DNase	NULL
I-hypersensitive	NULL
sites	NULL
are	NULL
located	NULL
)	NULL
,	NULL
various	NULL
Secl	NULL
and	NULL
BamHI	NULL
DNA	NULL
fragments	NULL
spanning	NULL
the	NULL
locus	NULL
were	NULL
cloned	NULL
into	NULL
a	NULL
pGL2	NULL
plasmid	NULL
containing	NULL
the	NULL
SV40	NULL
promoter	NULL
(	NULL
pGL2	NULL
promoter	NULL
)	NULL
or	NULL
p446	NULL
(	NULL
the	NULL
c-fes	NULL
promoter	NULL
)	NULL
.	NULL

The	NULL
1.4-kb	NULL
3	NULL
'	NULL
region	NULL
up	NULL
to	NULL
the	NULL
EcoRI	NULL
site	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
elevated	NULL
transient	NULL
expression	NULL
threefold	NULL
compared	NULL
with	NULL
either	NULL
the	NULL
pGL2	NULL
promoter	NULL
or	NULL
p446	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
our	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
strongest	NULL
positive	NULL
,	NULL
cis-acting	NULL
DNA	NULL
elements	NULL
identified	NULL
by	NULL
transient-transfection	NULL
analyses	NULL
lie	NULL
within	NULL
the	NULL
first	NULL
446	NULL
bp	NULL
5	NULL
'	NULL
of	NULL
the	NULL
primary	NULL
mRNA	NULL
cap	NULL
site	NULL
.	NULL

Although	NULL
a	NULL
weak	NULL
3	NULL
'	NULL
enhancer	NULL
element	NULL
was	NULL
identified	NULL
by	NULL
our	NULL
experiments	NULL
,	NULL
we	NULL
focused	NULL
on	NULL
the	NULL
446-bp	NULL
5	NULL
'	NULL
-flanking	NULL
region	NULL
.	NULL

To	NULL
further	NULL
localize	NULL
cis-acting	NULL
elements	NULL
in	NULL
the	NULL
446-bp	NULL
c-fes	NULL
promoter	NULL
,	NULL
deletion	NULL
analyses	NULL
were	NULL
performed	NULL
.	NULL

A	NULL
schematic	NULL
rep	NULL
resentation	NULL
of	NULL
the	NULL
luciferase	NULL
constructs	NULL
tested	NULL
by	NULL
transfection	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
.	NULL

DNA	NULL
sequences	NULL
located	NULL
between	NULL
nucleotides	NULL
-446	NULL
and	NULL
-366	NULL
were	NULL
largely	NULL
dispensable	NULL
for	NULL
transient	NULL
expression	NULL
,	NULL
as	NULL
luciferase	NULL
activity	NULL
in	NULL
U937	NULL
cells	NULL
dropped	NULL
only	NULL
10	NULL
%	NULL
if	NULL
these	NULL
nucleotides	NULL
were	NULL
removed	NULL
from	NULL
the	NULL
5	NULL
'	NULL
end	NULL
.	NULL

Plasmid	NULL
p251	NULL
(	NULL
containing	NULL
251	NULL
bp	NULL
of	NULL
5	NULL
'	NULL
sequences	NULL
)	NULL
retained	NULL
77	NULL
%	NULL
of	NULL
promoter	NULL
activity	NULL
compared	NULL
with	NULL
p446	NULL
.	NULL

However	NULL
,	NULL
when	NULL
the	NULL
region	NULL
between	NULL
-251	NULL
and	NULL
-151	NULL
was	NULL
deleted	NULL
,	NULL
expression	NULL
was	NULL
reduced	NULL
to	NULL
38	NULL
%	NULL
.	NULL

Finally	NULL
,	NULL
deletion	NULL
of	NULL
bp	NULL
-99	NULL
to	NULL
-51	NULL
essentially	NULL
decreased	NULL
activity	NULL
to	NULL
less	NULL
than	NULL
1	NULL
%	NULL
of	NULL
that	NULL
observed	NULL
with	NULL
p446	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
two	NULL
important	NULL
functional	NULL
domains	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
reside	NULL
within	NULL
nucleotides	NULL
extending	NULL
from	NULL
-251	NULL
to	NULL
-151	NULL
and	NULL
from	NULL
-99	NULL
to	NULL
-51	NULL
upstream	NULL
of	NULL
the	NULL
primary	NULL
site	NULL
of	NULL
transcription	NULL
initiation	NULL
.	NULL

The	NULL
¢-fes	NULL
genomic	NULL
locus	NULL
contains	NULL
a	NULL
myeloid-cell-specific	NULL
promoter	NULL
.	NULL

The	NULL
13-kb	NULL
human	NULL
c-fes	NULL
transgene	NULL
is	NULL
expressed	NULL
in	NULL
a	NULL
tissue-specific	NULL
manner	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
the	NULL
446-bp	NULL
c-fes	NULL
5	NULL
promoter	NULL
was	NULL
also	NULL
myeloid	NULL
cell	NULL
specific	NULL
,	NULL
the	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
,	NULL
p446	NULL
,	NULL
was	NULL
transiently	NULL
transfected	NULL
into	NULL
myeloid	NULL
and	NULL
nonmyeloid	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
The	NULL
promoterless	NULL
plasmid	NULL
pGL2	NULL
produced	NULL
low	NULL
levels	NULL
of	NULL
luciferase	NULL
activity	NULL
in	NULL
all	NULL
four	NULL
cell	NULL
lines	NULL
tested	NULL
.	NULL

p446	NULL
was	NULL
expressed	NULL
at	NULL
high	NULL
levels	NULL
in	NULL
two	NULL
myeloid	NULL
cell	NULL
lines	NULL
(	NULL
K562	NULL
and	NULL
U937	NULL
)	NULL
and	NULL
was	NULL
at	NULL
least	NULL
100	NULL
times	NULL
more	NULL
active	NULL
than	NULL
in	NULL
the	NULL
nonmyeloid	NULL
cells	NULL
(	NULL
Cos	NULL
and	NULL
HeLa	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
446-bp	NULL
5'-flanking	NULL
region	NULL
elevated	NULL
luciferase	NULL
activity	NULL
186-fold	NULL
over	NULL
pGL2	NULL
in	NULL
K562	NULL
cells	NULL
and	NULL
115,000-fold	NULL
over	NULL
pGL2	NULL
in	NULL
U937	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
differ	NULL
significantly	NULL
from	NULL
the	NULL
3-fold	NULL
stimulation	NULL
observed	NULL
in	NULL
Cos	NULL
cells	NULL
(	NULL
p446	NULL
versus	NULL
pGL2	NULL
)	NULL
and	NULL
the	NULL
1.3-fold	NULL
stimulation	NULL
seen	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
p446	NULL
was	NULL
not	NULL
active	NULL
in	NULL
the	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
reference	NULL
GH	NULL
levels	NULL
for	NULL
K562	NULL
,	NULL
Cos	NULL
,	NULL
and	NULL
HeLa	NULL
cells	NULL
were	NULL
identical	NULL
and	NULL
that	NULL
U937	NULL
cells	NULL
gave	NULL
values	NULL
two-	NULL
to	NULL
threefold	NULL
lower	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
5	NULL
'	NULL
sequences	NULL
upstream	NULL
of	NULL
the	NULL
c-fes	NULL
transcription	NULL
initiation	NULL
site	NULL
contain	NULL
a	NULL
promoter	NULL
that	NULL
is	NULL
active	NULL
in	NULL
a	NULL
myeloid-cell-specific	NULL
fashion	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
we	NULL
predicted	NULL
that	NULL
the	NULL
Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
A	NULL
REGULATION	NULL
OF	NULL
c-fes	NULL
BY	NULL
A	NULL
NOVEL	NULL
TRANSCRIPTION	NULL
FACTOR	NULL
1679	NULL
Mean	NULL
Value	NULL
RLU/ng	NULL
1071870	NULL
-	NULL
446	NULL
+71	NULL
231061	NULL
25	NULL
I	NULL
I	NULL
I	NULL
I	NULL
if	NULL
!	NULL

I	NULL
=	NULL
]	NULL
&	NULL
o	NULL
o	NULL
=	NULL
]	NULL
&	NULL
@	NULL
®	NULL
o	NULL
=	NULL
]	NULL
®	NULL
®	NULL
(	NULL
-	NULL
]	NULL
o	NULL
O	NULL
(	NULL
-	NULL
]	NULL
=	NULL
]	NULL
=	NULL
]	NULL
@	NULL
@	NULL
O	NULL
&	NULL
o	NULL
®	NULL
l-	NULL
]	NULL
=-	NULL
BJ	NULL
&	NULL
2	NULL
$	NULL
2	NULL
Promoter	NULL
Activity	NULL
Relative	NULL
Light	NULL
Units/ng	NULL
Growth	NULL
Hormone	NULL
Activity	NULL
(	NULL
%	NULL
)	NULL
-	NULL
446	NULL
+71	NULL
ase	NULL
100	NULL
~	NULL
91	NULL
Tg	NULL
T7	NULL
-	NULL
99	NULL
_tuciferase	NULL
]	NULL
38	NULL
ar	NULL
J	NULL
0.4	NULL
0.001	NULL
0	NULL
50000	NULL
100000	NULL
150000	NULL
200000	NULL
250000	NULL
Promoter	NULL
Activity	NULL
Relative	NULL
Light	NULL
Units/ng	NULL
Growth	NULL
Hormone	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
5'-flanking	NULL
region	NULL
of	NULL
c-fes	NULL
includes	NULL
a	NULL
promoter	NULL
that	NULL
is	NULL
active	NULL
in	NULL
myeloid	NULL
cells	NULL
.	NULL

One	NULL
hundred	NULL
micrograms	NULL
of	NULL
each	NULL
of	NULL
the	NULL
three	NULL
plasmids	NULL
shown	NULL
was	NULL
transfected	NULL
into	NULL
U937	NULL
cells	NULL
with	NULL
2	NULL
ug	NULL
of	NULL
pCMV-GH	NULL
reference	NULL
plasmid	NULL
.	NULL

To	NULL
normalize	NULL
for	NULL
transfection	NULL
efficiency	NULL
,	NULL
data	NULL
are	NULL
expressed	NULL
as	NULL
relative	NULL
light	NULL
units	NULL
of	NULL
luciferase	NULL
activity	NULL
per	NULL
nanogram	NULL
of	NULL
GH	NULL
secreted	NULL
.	NULL

Constructs	NULL
are	NULL
shown	NULL
schematically	NULL
at	NULL
the	NULL
left	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Functional	NULL
analysis	NULL
of	NULL
the	NULL
446-bp	NULL
c-fes	NULL
promoter	NULL
by	NULL
5	NULL
deletions	NULL
in	NULL
U937	NULL
cells	NULL
.	NULL

One	NULL
hundred	NULL
micrograms	NULL
of	NULL
each	NULL
of	NULL
the	NULL
c-fes	NULL
luciferase	NULL
reporter	NULL
plasmids	NULL
was	NULL
electroporated	NULL
with	NULL
2	NULL
pg	NULL
of	NULL
pCMV-GH	NULL
.	NULL

Each	NULL
construct	NULL
was	NULL
electroporated	NULL
3	NULL
to	NULL
10	NULL
times	NULL
with	NULL
different	NULL
preparations	NULL
of	NULL
plasmid	NULL
DNA	NULL
,	NULL
and	NULL
the	NULL
data	NULL
are	NULL
average	NULL
values	NULL
of	NULL
these	NULL
experiments	NULL
.	NULL

RSV	NULL
,	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
.	NULL

c-fes	NULL
promoter	NULL
would	NULL
be	NULL
active	NULL
in	NULL
K562	NULL
cells	NULL
even	NULL
though	NULL
they	NULL
express	NULL
low	NULL
levels	NULL
of	NULL
the	NULL
endogenous	NULL
gene	NULL
because	NULL
the	NULL
13-kb	NULL
c-fes	NULL
transgene	NULL
is	NULL
active	NULL
when	NULL
introduced	NULL
into	NULL
this	NULL
cell	NULL
line	NULL
.	NULL

As	NULL
stated	NULL
previously	NULL
,	NULL
stable	NULL
K562	NULL
transformants	NULL
containing	NULL
the	NULL
transgene	NULL
synthesize	NULL
high	NULL
levels	NULL
of	NULL
c-fes	NULL
mRNA	NULL
and	NULL
protein	NULL
and	NULL
exhibit	NULL
high	NULL
levels	NULL
of	NULL
kinase	NULL
activity	NULL
(	NULL
40	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
the	NULL
previous	NULL
section	NULL
,	NULL
a	NULL
plasmid	NULL
containing	NULL
151	NULL
bp	NULL
of	NULL
5	NULL
'	NULL
c-fes	NULL
sequences	NULL
linked	NULL
to	NULL
luciferase	NULL
was	NULL
less	NULL
active	NULL
in	NULL
U937	NULL
cells	NULL
than	NULL
one	NULL
containing	NULL
446	NULL
bp	NULL
but	NULL
still	NULL
resulted	NULL
in	NULL
40,000-fold-higher	NULL
activity	NULL
than	NULL
pGL2	NULL
.	NULL

To	NULL
learn	NULL
if	NULL
the	NULL
151-bp	NULL
region	NULL
is	NULL
regulated	NULL
in	NULL
a	NULL
myeloid-cell-specific	NULL
pattern	NULL
,	NULL
p151	NULL
was	NULL
transiently	NULL
transfected	NULL
into	NULL
U937	NULL
,	NULL
K562	NULL
,	NULL
Cos	NULL
,	NULL
and	NULL
3T3	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
p151	NULL
generated	NULL
luciferase	NULL
activity	NULL
at	NULL
levels	NULL
20-	NULL
to	NULL
30-fold	NULL
higher	NULL
in	NULL
K562	NULL
and	NULL
U937	NULL
cells	NULL
than	NULL
in	NULL
3T3	NULL
and	NULL
Cos	NULL
cells	NULL
and	NULL
thereby	NULL
retained	NULL
tissue-specific	NULL
expression	NULL
.	NULL

Sp1	NULL
interacts	NULL
with	NULL
the	NULL
c-fes	NULL
promoter	NULL
.	NULL

To	NULL
identify	NULL
nuclear	NULL
protein	NULL
binding	NULL
sites	NULL
within	NULL
the	NULL
446-bp	NULL
c-fes	NULL
promoter	NULL
,	NULL
DNase	NULL
I	NULL
footprinting	NULL
analyses	NULL
were	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
U937	NULL
cells	NULL
.	NULL

Four	NULL
nuclear	NULL
protein	NULL
binding	NULL
sites	NULL
were	NULL
identified	NULL
in	NULL
these	NULL
experiments	NULL
,	NULL
and	NULL
the	NULL
data	NULL
are	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

The	NULL
first	NULL
footprint	NULL
(	NULL
FP1	NULL
)	NULL
extends	NULL
from	NULL
bp	NULL
-408	NULL
to	NULL
-386	NULL
and	NULL
does	NULL
not	NULL
contain	NULL
a	NULL
previously	NULL
described	NULL
consensus	NULL
motif	NULL
.	NULL

The	NULL
second	NULL
nuclear	NULL
protein	NULL
binding	NULL
site	NULL
(	NULL
FP2	NULL
)	NULL
extends	NULL
from	NULL
bp	NULL
-293	NULL
to	NULL
-254	NULL
and	NULL
includes	NULL
a	NULL
consensus	NULL
nuclear	NULL
pro	NULL
tein	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
transcription	NULL
factor	NULL
Spl	NULL
(	NULL
-293	NULL
to	NULL
-285	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
neither	NULL
of	NULL
these	NULL
two	NULL
nuclear	NULL
protein	NULL
binding	NULL
sites	NULL
was	NULL
absolutely	NULL
required	NULL
for	NULL
the	NULL
in	NULL
vitro	NULL
activity	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
p251	NULL
retained	NULL
77	NULL
%	NULL
of	NULL
full	NULL
promoter	NULL
activity	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
third	NULL
footprint	NULL
(	NULL
FP3	NULL
)	NULL
includes	NULL
nucleotides	NULL
-76	NULL
to	NULL
-65	NULL
and	NULL
contains	NULL
one	NULL
DNase	NULL
I-hypersensitive	NULL
site	NULL
.	NULL

This	NULL
region	NULL
,	NULL
which	NULL
is	NULL
footprinted	NULL
weakly	NULL
compared	NULL
with	NULL
the	NULL
other	NULL
footprints	NULL
,	NULL
contains	NULL
three	NULL
potential	NULL
nuclear	NULL
protein	NULL
binding	NULL
sites	NULL
for	NULL
the	NULL
ubiquitous	NULL
transcription	NULL
factor	NULL
Spl	NULL
.	NULL

Sp1	NULL
sites	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
several	NULL
other	NULL
transcriptional	NULL
regulatory	NULL
elements	NULL
that	NULL
are	NULL
present	NULL
in	NULL
myeloid-cell-specific	NULL
genes	NULL
,	NULL
including	NULL
CD11b	NULL
(	NULL
21	NULL
)	NULL
.	NULL

The	NULL
fourth	NULL
nuclear	NULL
protein	NULL
binding	NULL
site	NULL
(	NULL
FP4	NULL
)	NULL
extends	NULL
from	NULL
-34	NULL
to	NULL
+1	NULL
on	NULL
the	NULL
antisense	NULL
strand	NULL
and	NULL
from	NULL
-34	NULL
to	NULL
+3	NULL
on	NULL
the	NULL
sense	NULL
strand	NULL
and	NULL
is	NULL
also	NULL
surrounded	NULL
by	NULL
several	NULL
hypersensitive	NULL
sites	NULL
.	NULL

This	NULL
region	NULL
contains	NULL
a	NULL
consensus	NULL
Ets	NULL
family	NULL
member	NULL
binding	NULL
site	NULL
(	NULL
-21	NULL
to	NULL
=-11	NULL
)	NULL
and	NULL
a	NULL
nonconsensus	NULL
AP-1	NULL
binding	NULL
site	NULL
(	NULL
-10	NULL
to	NULL
-3	NULL
)	NULL
.	NULL

Comparison	NULL
of	NULL
this	NULL
sequence	NULL
with	NULL
other	NULL
previously	NULL
described	NULL
Ets	NULL
binding	NULL
sites	NULL
suggests	NULL
that	NULL
this	NULL
motif	NULL
can	NULL
bind	NULL
to	NULL
either	NULL
or	NULL
both	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
Elf-1	NULL
and	NULL
PU.1	NULL
but	NULL
not	NULL
to	NULL
Ets-1	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
as	NULL
is	NULL
the	NULL
case	NULL
for	NULL
multiple	NULL
other	NULL
Ets	NULL
binding	NULL
sites	NULL
(	NULL
9	NULL
,	NULL
34	NULL
,	NULL
37	NULL
)	NULL
,	NULL
this	NULL
region	NULL
is	NULL
immediately	NULL
adjacent	NULL
to	NULL
a	NULL
nonconsensus	NULL
AP-1	NULL
family	NULL
member	NULL
nuclear	NULL
protein	NULL
binding	NULL
site	NULL
(	NULL
5'-TGATTCC-3	NULL
'	NULL
,	NULL
nucleotides	NULL
-10	NULL
to	NULL
-3	NULL
on	NULL
the	NULL
opposite	NULL
strand	NULL
)	NULL
.	NULL

1680	NULL
HEYDEMANN	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

Mean	NULL
Value	NULL
RLU/ng	NULL
446	NULL
71	NULL
;	NULL
Luciferase	NULL
Luciferase	NULL
304078	NULL
206541	NULL
500007	NULL
1000007	NULL
1500007	NULL
200000-2500007	NULL
3000007	NULL
350000	NULL
Promoter	NULL
Activity	NULL
Relative	NULL
Light	NULL
Units/ng	NULL
Growth	NULL
Hormone	NULL
Mean	NULL
Value	NULL
RLU/ng	NULL
151	NULL
y=	NULL
I-+	NULL
64022	NULL
66639	NULL
Luciferase	NULL
10000	NULL
20000	NULL
30000	NULL
40000	NULL
50000	NULL
60000	NULL
90000	NULL
Promoter	NULL
Activity	NULL
Relative	NULL
Light	NULL
Units/ng	NULL
Growth	NULL
Hormone	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Functional	NULL
analysis	NULL
of	NULL
the	NULL
446-bp	NULL
5	NULL
'	NULL
promoter	NULL
of	NULL
the	NULL
human	NULL
c-fes	NULL
gene	NULL
in	NULL
myeloid	NULL
and	NULL
nonmyeloid	NULL
cell	NULL
lines	NULL
.	NULL

K562	NULL
,	NULL
U937	NULL
,	NULL
Cos	NULL
,	NULL
and	NULL
HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
luciferase	NULL
construct	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
.	NULL

K562	NULL
and	NULL
U937	NULL
cells	NULL
were	NULL
transfected	NULL
for	NULL
13	NULL
h	NULL
and	NULL
Cos	NULL
and	NULL
HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
for	NULL
48	NULL
h.	NULL
Each	NULL
construct	NULL
was	NULL
transfected	NULL
3	NULL
to	NULL
10	NULL
times	NULL
with	NULL
different	NULL
preparations	NULL
of	NULL
plasmid	NULL
DNA	NULL
,	NULL
and	NULL
the	NULL
data	NULL
are	NULL
averages	NULL
of	NULL
these	NULL
experiments	NULL
.	NULL

The	NULL
reference	NULL
plasmid	NULL
,	NULL
pCMV-GH	NULL
,	NULL
produced	NULL
similar	NULL
levels	NULL
of	NULL
GH	NULL
in	NULL
all	NULL
cell	NULL
lines	NULL
transfected	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Functional	NULL
analysis	NULL
of	NULL
the	NULL
151-bp	NULL
5	NULL
'	NULL
region	NULL
in	NULL
K562	NULL
,	NULL
U937	NULL
,	NULL
Cos	NULL
,	NULL
and	NULL
3T3	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
by	NULL
computer	NULL
search	NULL
analyses	NULL
,	NULL
there	NULL
are	NULL
three	NULL
putative	NULL
Spl	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
core	NULL
c-fes	NULL
promoter	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
Spl	NULL
interacts	NULL
with	NULL
the	NULL
promoter	NULL
,	NULL
EMSAs	NULL
were	NULL
conducted	NULL
with	NULL
an	NULL
oligonucleotide	NULL
probe	NULL
that	NULL
includes	NULL
these	NULL
three	NULL
putative	NULL
Spl	NULL
binding	NULL
sites	NULL
and	NULL
extends	NULL
from	NULL
bp	NULL
-93	NULL
to	NULL
-46	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
first	NULL
three	NULL
lanes	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
exhibit	NULL
results	NULL
obtained	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
HeLa	NULL
,	NULL
U937	NULL
,	NULL
and	NULL
K562	NULL
cells	NULL
respectively	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
all	NULL
three	NULL
cell	NULL
lines	NULL
contained	NULL
DNA	NULL
binding	NULL
activities	NULL
for	NULL
the	NULL
ubiquitous	NULL
Sp1	NULL
protein	NULL
when	NULL
incubated	NULL
with	NULL
this	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

To	NULL
test	NULL
the	NULL
specific-ity	NULL
of	NULL
binding	NULL
,	NULL
the	NULL
assays	NULL
that	NULL
are	NULL
shown	NULL
in	NULL
lanes	NULL
4	NULL
through	NULL
6	NULL
of	NULL
Fig	NULL
.	NULL

5	NULL
also	NULL
contained	NULL
various	NULL
cold	NULL
competitor	NULL
DNAs	NULL
.	NULL

A	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
identical	NULL
c-fes	NULL
oligonucleotide	NULL
effectively	NULL
inhibited	NULL
DNA	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

An	NULL
unrelated	NULL
oligonucleotide	NULL
that	NULL
includes	NULL
a	NULL
consensus	NULL
Spl	NULL
site	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
also	NULL
competed	NULL
for	NULL
this	NULL
DNA-protein	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

However	NULL
,	NULL
another	NULL
unrelated	NULL
oligonucleotide	NULL
(	NULL
PU.1	NULL
)	NULL
corresponding	NULL
to	NULL
32	NULL
bp	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
(	NULL
-32	NULL
to	NULL
=1	NULL
)	NULL
that	NULL
includes	NULL
a	NULL
PU.1/Elf-1	NULL
binding	NULL
site	NULL
did	NULL
not	NULL
compete	NULL
for	NULL
this	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
an	NULL
antibody	NULL
against	NULL
Sp1	NULL
caused	NULL
a	NULL
supershift	NULL
of	NULL
the	NULL
DNA-protein	NULL
complex	NULL
in	NULL
K562	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

These	NULL
results	NULL
strongly	NULL
suggest	NULL
that	NULL
transcription	NULL
factor	NULL
Sp1	NULL
binds	NULL
in	NULL
vitro	NULL
to	NULL
at	NULL
least	NULL
-446	NULL
Epi	NULL
(	NULL
IEAATTCCGTGAGGTGGGGAGGGCTGGGACCAGGGTTC	NULL
-366	NULL
[	NULL
Erescoreerecoraceacrecececomrcecorcacraccescesacaccerecserrece	NULL
Sp1	NULL
FP2	NULL
TGGGCCCAGCATCTGCCTG	NULL
@	NULL
eeCccTceccr	NULL
WM	NULL
-251	NULL
o	NULL
[	NULL
pcompecceeremreccsceecooreccaseccomreccecomrececsececesececerc	NULL
~151	NULL
mrecomescccamrommmeccesceccorcopceommecemmccoreecceTeccecce	NULL
-99	NULL
comaeacecreceecccaccececaccaceeccecreccacecerceceaccercecace	NULL
Sp1	NULL
FP3	NULL
Spi	NULL
Sp1	NULL
'	NULL
5.1	NULL
comecoscocpeccompeccomrcacaseeccececcecseccrecsccaacfearacce	NULL
]	NULL
Fp4	NULL
1	NULL
a	NULL
a	NULL
~PUAZEIM	NULL
-	NULL
paz	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
c-fes	NULL
446-bp	NULL
5	NULL
'	NULL
region	NULL
.	NULL

Nuclear	NULL
protein	NULL
binding	NULL
sites	NULL
identified	NULL
with	NULL
U937	NULL
nuclear	NULL
extracts	NULL
and	NULL
footprint	NULL
analyses	NULL
are	NULL
boxed	NULL
.	NULL

Filled	NULL
circles	NULL
above	NULL
the	NULL
sequence	NULL
indicate	NULL
hypersensitive	NULL
sites	NULL
on	NULL
the	NULL
sense	NULL
strand	NULL
,	NULL
and	NULL
those	NULL
below	NULL
represent	NULL
hypersensitive	NULL
sites	NULL
on	NULL
the	NULL
antisense	NULL
strand	NULL
.	NULL

Consensus	NULL
sites	NULL
for	NULL
Sp1	NULL
and	NULL
PU.1/EIf-1	NULL
are	NULL
underlined	NULL
.	NULL

A	NULL
nonconsensus	NULL
AP-1	NULL
site	NULL
,	NULL
5'-TGATTCC-3	NULL
'	NULL
,	NULL
is	NULL
on	NULL
the	NULL
opposite	NULL
strand	NULL
.	NULL

FP4-3	NULL
'	NULL
is	NULL
underlined	NULL
.	NULL

The	NULL
primary	NULL
mRNA	NULL
cap	NULL
site	NULL
is	NULL
indicated	NULL
by	NULL
an	NULL
arrow	NULL
.	NULL

CGGGGTCCecAacces	NULL
@	NULL
ccrcactceere	NULL
Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
A	NULL
B	NULL
®	NULL
on	NULL
a	NULL
>	NULL
:	NULL
IK	NULL
1	NULL
.	NULL

Extract	NULL
:	NULL
i	NULL
,	NULL
g	NULL
L	NULL
Extract	NULL
:	NULL
563	NULL
$	NULL
&	NULL
is	NULL
=o	NULL
Z	NULL
Antibody	NULL
:	NULL
-	NULL
&	NULL
>	NULL
Competitor	NULL
:	NULL
-	NULL
8	NULL
.	NULL

&	NULL
2-	NULL
&	NULL
=C	NULL
-	NULL
»	NULL
-*	NULL
»	NULL
lii	NULL
dow	NULL
2	NULL
-~3	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
\n	NULL
t	NULL
@	NULL
___	NULL
``	NULL
2	NULL
M	NULL
2	NULL
UU	NULL
11	NULL
2	NULL
3	NULL
|	NULL
Probe	NULL
:	NULL
c-fes	NULL
-93/-46	NULL
Probe	NULL
:	NULL
c-fes	NULL
-93/-46	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

EMSA	NULL
by	NULL
using	NULL
radiolabeled	NULL
c-fes	NULL
oligonucleotide	NULL
probes	NULL
extending	NULL
from	NULL
-93	NULL
to	NULL
-46	NULL
with	NULL
nuclear	NULL
protein	NULL
extracts	NULL
prepared	NULL
from	NULL
HeLa	NULL
,	NULL
U937	NULL
,	NULL
and	NULL
K562	NULL
human	NULL
cell	NULL
lines	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSA	NULL
with	NULL
the	NULL
indicated	NULL
competing	NULL
oligonucleotides	NULL
in	NULL
lanes	NULL
4	NULL
through	NULL
6	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
100	NULL
ng	NULL
(	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
)	NULL
of	NULL
an	NULL
unlabeled	NULL
competitor	NULL
oligonucleotide	NULL
was	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reactions	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSA	NULL
with	NULL
the	NULL
addition	NULL
of	NULL
antibody	NULL
that	NULL
specifically	NULL
reacts	NULL
with	NULL
the	NULL
human	NULL
Sp1	NULL
protein	NULL
.	NULL

Arrows	NULL
,	NULL
Sp1	NULL
complex	NULL
;	NULL
dashed	NULL
arrow	NULL
,	NULL
Sp1	NULL
supershifted	NULL
complex	NULL
.	NULL

REGULATION	NULL
OF	NULL
c-fes	NULL
BY	NULL
A	NULL
NOVEL	NULL
TRANSCRIPTION	NULL
FACTOR	NULL
1681	NULL
one	NULL
of	NULL
the	NULL
three	NULL
consensus	NULL
Sp1	NULL
sites	NULL
in	NULL
this	NULL
portion	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
.	NULL

The	NULL
PU.1/Elf-1	NULL
and	NULL
FP4-3	NULL
'	NULL
sites	NULL
are	NULL
required	NULL
for	NULL
c-fes	NULL
promoter	NULL
activity	NULL
in	NULL
myeloid	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
a	NULL
construct	NULL
containing	NULL
51	NULL
bp	NULL
of	NULL
5	NULL
'	NULL
c-fes	NULL
sequences	NULL
was	NULL
inactive	NULL
in	NULL
transient	NULL
assays	NULL
.	NULL

However	NULL
,	NULL
a	NULL
footprinted	NULL
region	NULL
(	NULL
FP4	NULL
,	NULL
from	NULL
-34	NULL
to	NULL
+3	NULL
)	NULL
was	NULL
detected	NULL
by	NULL
DNase	NULL
I	NULL
protection	NULL
analyses	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
tested	NULL
specific	NULL
mutations	NULL
in	NULL
this	NULL
footprinted	NULL
region	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
entire	NULL
446-bp	NULL
promoter	NULL
by	NULL
transient	NULL
transfections	NULL
.	NULL

Figure	NULL
6A	NULL
shows	NULL
that	NULL
promoter	NULL
activity	NULL
in	NULL
U937	NULL
cells	NULL
is	NULL
sharply	NULL
reduced	NULL
(	NULL
by	NULL
approximately	NULL
90	NULL
%	NULL
)	NULL
if	NULL
the	NULL
PU.1/Elf-1	NULL
DNA	NULL
binding	NULL
site	NULL
is	NULL
changed	NULL
from	NULL
5'-GAGGAGGAAGCG	NULL
C-3	NULL
'	NULL
to	NULL
5-GAGCACCGGGCGC-3	NULL
'	NULL
,	NULL
a	NULL
mutation	NULL
that	NULL
renders	NULL
it	NULL
incapable	NULL
of	NULL
binding	NULL
PU.1	NULL
or	NULL
Elf-1	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
flanking	NULL
site	NULL
FP4-3	NULL
'	NULL
(	NULL
which	NULL
does	NULL
not	NULL
affect	NULL
PU.1	NULL
DNA	NULL
binding	NULL
activity	NULL
)	NULL
from	NULL
5-TGATTCC-3	NULL
'	NULL
to	NULL
TGGC-3	NULL
'	NULL
resulted	NULL
in	NULL
an	NULL
80	NULL
%	NULL
decrease	NULL
in	NULL
expression	NULL
compared	NULL
with	NULL
the	NULL
wild-type	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
strongly	NULL
suggest	NULL
that	NULL
important	NULL
regulators	NULL
for	NULL
c-fes	NULL
expression	NULL
include	NULL
Sp1	NULL
and	NULL
PU.1	NULL
or	NULL
Elf-1	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
either	NULL
AP-1	NULL
or	NULL
another	NULL
DNA-binding	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
binding	NULL
to	NULL
FP4-3	NULL
'	NULL
also	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
c-fes	NULL
in	NULL
myeloid	NULL
cells	NULL
.	NULL

PU.1	NULL
and	NULL
Elf-1	NULL
bind	NULL
to	NULL
the	NULL
Ets	NULL
site	NULL
in	NULL
the	NULL
c-fes	NULL
promoter	NULL
,	NULL
but	NULL
AP-1	NULL
family	NULL
members	NULL
do	NULL
not	NULL
bind	NULL
to	NULL
FP4-3	NULL
'	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
experiments	NULL
demonstrated	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
nuclear	NULL
protein	NULL
binding	NULL
site	NULL
within	NULL
the	NULL
c-fes	NULL
promoter	NULL
that	NULL
could	NULL
potentially	NULL
bind	NULL
both	NULL
Ets	NULL
and	NULL
AP-1	NULL
family	NULL
members	NULL
.	NULL

c-fes	NULL
lacks	NULL
a	NULL
functional	NULL
TATA	NULL
box	NULL
and	NULL
has	NULL
the	NULL
sequence	NULL
Activity	NULL
(	NULL
%	NULL
)	NULL
$	NULL
s	NULL
T	NULL
-P	NULL
Pu	NULL
.	NULL

_+	NULL
100	NULL
to	NULL
FPA-3	NULL
'	NULL
<	NULL
=-	NULL
<	NULL
FP43	NULL
'	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
f=3	NULL
o	NULL
f=4	NULL
f=3	NULL
f=3	NULL
f=	NULL
f=	NULL
o	NULL
f=	NULL
f=	NULL
o	NULL
g	NULL
J	NULL
<	NULL
4	NULL
«	NULL
©	NULL
co	NULL
y=	NULL
Promoter	NULL
Activity	NULL
B	NULL
Relative	NULL
Light	NULL
Units/ng	NULL
Growth	NULL
Hormone	NULL
Activity	NULL
(	NULL
%	NULL
)	NULL
$	NULL
s	NULL
a	NULL
pu	NULL
.	NULL

t	NULL
100	NULL
l	NULL
FP43	NULL
'	NULL
f	NULL
<	NULL
m	NULL
t	NULL
pu.1	NULL
,	NULL
_+	NULL
24	NULL
FPA4-3	NULL
'	NULL
jf	NULL
Pb	NULL
PPP	NULL
f	NULL
Promoter	NULL
Activity	NULL
Relative	NULL
Light	NULL
Units/ng	NULL
Growth	NULL
Hormone	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Functional	NULL
analysis	NULL
of	NULL
the	NULL
PU.1/EIf-1	NULL
and	NULL
FP4-3	NULL
'	NULL
sites	NULL
in	NULL
U937	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
446-bp	NULL
promoter	NULL
with	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
PU.1/EIf-1	NULL
site	NULL
was	NULL
electroporated	NULL
into	NULL
U937	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
446-bp	NULL
promoter	NULL
with	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
adjacent	NULL
FP4-3	NULL
'	NULL
site	NULL
was	NULL
electroporated	NULL
into	NULL
U937	NULL
cells	NULL
.	NULL

1682	NULL
HEYDEMANN	NULL
ET	NULL
AL	NULL
.	NULL

3	NULL
&	NULL
n.	NULL
l	NULL
Extract	NULL
:	NULL
!	NULL

-	NULL
uss	NULL
?	NULL

l	NULL
;	NULL
&	NULL
5	NULL
!	NULL

!	NULL

qu	NULL
3	NULL
itor	NULL
:	NULL
~	NULL
3	NULL
£09909	NULL
0+	NULL
+	NULL
Competitor	NULL
:	NULL
2	NULL
2	NULL
Antibody	NULL
:	NULL
-	NULL
-	NULL
-	NULL
.	NULL

--	NULL
2~u_	NULL
:	NULL
'	NULL
L	NULL
8	NULL
%	NULL
«	NULL
4=	NULL
--	NULL
<	NULL
+n	NULL
~	NULL
Elf1-	NULL
»	NULL
3C	NULL
‘	NULL
us-	NULL
»	NULL
tb	NULL
«	NULL
pao	NULL
PU	NULL
.	NULL

1-	NULL
»	NULL
*	NULL
|	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8s	NULL
9	NULL
,	NULL
c-fes	NULL
-32/-1	NULL
Probe	NULL
:	NULL
PU.1	NULL
:	NULL
_	NULL
GAGGAGGAAGCGC	NULL
PU	NULL
.	NULL

Aimut	NULL
:	NULL
-	NULL
~	NULL
--	NULL
--	NULL
-	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

Extract	NULL
:	NULL
!	NULL

U937	NULL
1	NULL
ju	NULL
3	NULL
+O	NULL
*T	NULL
[	NULL
3	NULL
£00.00	NULL
}	NULL
00	NULL
%	NULL
Competitor	NULL
:	NULL
*	NULL
-o	NULL
ror	NULL
8	NULL
3	NULL
3	NULL
d	NULL
?	NULL

a	NULL
a	NULL
<	NULL
s	NULL
505	NULL
&	NULL
Antibody	NULL
:	NULL
-	NULL
-	NULL
-	NULL
-O	NULL
40	NULL
rf	NULL
t	NULL
\	NULL
Clip	NULL
wo	NULL
+	NULL
am	NULL
~	NULL
a	NULL
--	NULL
-FP4-3	NULL
'	NULL
-p	NULL
51	NULL
pa	NULL
Elf-1-	NULL
»	NULL
3	NULL
-	NULL
>	NULL
4	NULL
#	NULL
``	NULL
¥	NULL
%	NULL
=	NULL
PUA-	NULL
»	NULL
5	NULL
lid	NULL
@	NULL
b	NULL
wh	NULL
hos	NULL
a	NULL
*-	NULL
»	NULL
6	NULL
we	NULL
oue	NULL
cap	NULL
.	NULL

#	NULL
#	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8s	NULL
o	NULL
,	NULL
Probe	NULL
:	NULL
c-fes	NULL
-32/+14	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Investigation	NULL
of	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
PU.1/Elf-1	NULL
and	NULL
FP4-3	NULL
'	NULL
sites	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSA	NULL
by	NULL
using	NULL
radiolabeled	NULL
c-fes	NULL
probe	NULL
(	NULL
-32	NULL
to	NULL
-1	NULL
)	NULL
with	NULL
U937	NULL
nuclear	NULL
protein	NULL
extracts	NULL
and	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
and	NULL
Elf-1	NULL
proteins	NULL
.	NULL

Lanes	NULL
2	NULL
and	NULL
3	NULL
include	NULL
100	NULL
ng	NULL
of	NULL
the	NULL
indicated	NULL
unlabeled	NULL
competitor	NULL
oligonucleotide	NULL
.	NULL

Lane	NULL
6	NULL
contains	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
unprogrammed	NULL
reticulocyte	NULL
lysate	NULL
as	NULL
that	NULL
programmed	NULL
with	NULL
PU.1	NULL
pcDNA	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
and	NULL
Elf-1	NULL
pcDNA	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Lanes	NULL
7	NULL
and	NULL
8	NULL
include	NULL
the	NULL
indicated	NULL
antibodies	NULL
to	NULL
PU.1	NULL
and	NULL
Elf-1	NULL
.	NULL

The	NULL
mutated	NULL
nucleotides	NULL
in	NULL
the	NULL
mutant	NULL
PU.1	NULL
oligonucleotide	NULL
are	NULL
shown	NULL
below	NULL
the	NULL
autoradiogram	NULL
.	NULL

NS	NULL
,	NULL
nonspecific	NULL
nuclear	NULL
protein	NULL
complex	NULL
;	NULL
IVT	NULL
,	NULL
in	NULL
vitro	NULL
translated	NULL
;	NULL
RL	NULL
,	NULL
reticulocyte	NULL
lysate	NULL
.	NULL

Solid	NULL
arrows	NULL
,	NULL
DNA-protein	NULL
complexes	NULL
;	NULL
dashed	NULL
arrow	NULL
,	NULL
Elf-1	NULL
supershift	NULL
;	NULL
dotted	NULL
arrow	NULL
,	NULL
PU.1	NULL
supershift	NULL
;	NULL
asterisk	NULL
,	NULL
fastest-migrating	NULL
complex	NULL
;	NULL
«	NULL
,	NULL
anti	NULL
.	NULL

(	NULL
B	NULL
)	NULL
AP-1	NULL
family	NULL
members	NULL
failed	NULL
to	NULL
bind	NULL
to	NULL
a	NULL
c-fes	NULL
probe	NULL
extending	NULL
from	NULL
-32	NULL
to	NULL
+14	NULL
(	NULL
PU.1/FP4-3	NULL
'	NULL
)	NULL
.	NULL

Lanes	NULL
2	NULL
through	NULL
5	NULL
contain	NULL
100	NULL
ng	NULL
of	NULL
the	NULL
indicated	NULL
cold	NULL
competitor	NULL
oligonucleotide	NULL
.	NULL

Lanes	NULL
6	NULL
through	NULL
9	NULL
contain	NULL
the	NULL
indicated	NULL
antibodies	NULL
.	NULL

Numbers	NULL
at	NULL
left	NULL
indicate	NULL
bands	NULL
.	NULL

Dashed	NULL
arrow	NULL
,	NULL
Elf-1	NULL
supershift	NULL
.	NULL

AAGC-3	NULL
'	NULL
at	NULL
position	NULL
-21	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL

Myeloid	NULL
cells	NULL
express	NULL
the	NULL
Ets	NULL
family	NULL
members	NULL
Ets-1	NULL
,	NULL
Elf-1	NULL
,	NULL
and	NULL
PU.1	NULL
(	NULL
2b	NULL
,	NULL
16	NULL
)	NULL
.	NULL

Published	NULL
DNA	NULL
binding	NULL
site	NULL
specificities	NULL
indicate	NULL
that	NULL
the	NULL
c-fes	NULL
promoter	NULL
contains	NULL
a	NULL
consensus	NULL
Elf-1	NULL
and/or	NULL
PU.1	NULL
site	NULL
:	NULL
Ets-1	NULL
selectively	NULL
binds	NULL
G-3	NULL
'	NULL
,	NULL
while	NULL
both	NULL
Elf-1	NULL
and	NULL
PU.1	NULL
bind	NULL
the	NULL
5'-GAGGAGGAA	NULL
GC-3	NULL
'	NULL
sequence	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
myeloid-cell	NULL
nuclear	NULL
extracts	NULL
contain	NULL
Ets	NULL
binding	NULL
activities	NULL
that	NULL
recognize	NULL
this	NULL
region	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
,	NULL
EMSAs	NULL
were	NULL
performed	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
a	NULL
radiolabeled	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
bp	NULL
-32	NULL
to	NULL
-1	NULL
forms	NULL
multiple	NULL
nuclear	NULL
protein	NULL
complexes	NULL
with	NULL
extracts	NULL
prepared	NULL
from	NULL
U937	NULL
cells	NULL
.	NULL

Three	NULL
complexes	NULL
evince	NULL
specific	NULL
interactions	NULL
with	NULL
the	NULL
oligonucleotide	NULL
probe	NULL
because	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotide	NULL
competes	NULL
for	NULL
these	NULL
DNA	NULL
binding	NULL
activities	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

The	NULL
fourth	NULL
complex	NULL
,	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
nonspecific	NULL
,	NULL
as	NULL
an	NULL
oligonucleotide	NULL
with	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
Ets	NULL
site	NULL
also	NULL
competed	NULL
for	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
as	NULL
did	NULL
a	NULL
variety	NULL
of	NULL
oligonucleotides	NULL
with	NULL
dissimilar	NULL
sequences	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
have	NULL
determined	NULL
that	NULL
the	NULL
most	NULL
slowly	NULL
migrating	NULL
complex	NULL
contains	NULL
Elf-1	NULL
,	NULL
as	NULL
it	NULL
comigrates	NULL
with	NULL
in	NULL
vitro-translated	NULL
Elf-1	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
and	NULL
is	NULL
supershifted	NULL
with	NULL
a	NULL
monoclonal	NULL
antibody	NULL
that	NULL
specifically	NULL
recognizes	NULL
Elf-1	NULL
and	NULL
not	NULL
other	NULL
Ets	NULL
family	NULL
members	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
more	NULL
rapidly	NULL
migrating	NULL
complex	NULL
represents	NULL
PU.1	NULL
binding	NULL
to	NULL
the	NULL
Ets	NULL
site	NULL
,	NULL
as	NULL
it	NULL
comigrates	NULL
with	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
and	NULL
is	NULL
blocked	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
anti-PU.1	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

Both	NULL
antibodies	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
were	NULL
tested	NULL
with	NULL
pure	NULL
Elf-1	NULL
and	NULL
PU.1	NULL
proteins	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

8	NULL
;	NULL
also	NULL
,	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
fastest-migrating	NULL
complex	NULL
may	NULL
represent	NULL
a	NULL
proteolytic	NULL
product	NULL
of	NULL
PU.1	NULL
that	NULL
retains	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
not	NULL
possible	NULL
to	NULL
unequivocally	NULL
identify	NULL
this	NULL
protein	NULL
,	NULL
as	NULL
it	NULL
is	NULL
not	NULL
recognized	NULL
by	NULL
the	NULL
antibody	NULL
to	NULL
PU.1	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
AP-1	NULL
family	NULL
members	NULL
bind	NULL
to	NULL
the	NULL
nonconsensus	NULL
site	NULL
at	NULL
-10	NULL
to	NULL
-3	NULL
,	NULL
a	NULL
longer	NULL
oligonucleotide	NULL
which	NULL
extended	NULL
from	NULL
-32	NULL
to	NULL
+14	NULL
(	NULL
-32/+14	NULL
)	NULL
and	NULL
included	NULL
FP4-3	NULL
'	NULL
was	NULL
utilized	NULL
.	NULL

By	NULL
using	NULL
this	NULL
oligonucleotide	NULL
and	NULL
unstimulated	NULL
U937	NULL
nuclear	NULL
extracts	NULL
,	NULL
six	NULL
nuclear	NULL
protein	NULL
complexes	NULL
were	NULL
detected	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

The	NULL
upper	NULL
two	NULL
bands	NULL
in	NULL
Fig	NULL
.	NULL

7B	NULL
migrate	NULL
very	NULL
closely	NULL
together	NULL
and	NULL
are	NULL
resolved	NULL
best	NULL
in	NULL
lane	NULL
3	NULL
.	NULL

Band	NULL
three	NULL
corresponds	NULL
to	NULL
an	NULL
Elf-1	NULL
complex	NULL
because	NULL
it	NULL
can	NULL
be	NULL
supershifted	NULL
with	NULL
an	NULL
Elf-1-specific	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
bands	NULL
five	NULL
and	NULL
six	NULL
are	NULL
identified	NULL
as	NULL
PU.1	NULL
by	NULL
their	NULL
ablation	NULL
with	NULL
the	NULL
anti-PU.1	NULL
antibody	NULL
,	NULL
which	NULL
now	NULL
detects	NULL
both	NULL
intact	NULL
and	NULL
truncated	NULL
PU.1	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
proteolytic	NULL
product	NULL
of	NULL
PU.1	NULL
,	NULL
binding	NULL
reactions	NULL
were	NULL
modified	NULL
and	NULL
tested	NULL
with	NULL
antibodies	NULL
that	NULL
recognize	NULL
the	NULL
amino	NULL
terminus	NULL
(	NULL
Santa	NULL
Cruz	NULL
)	NULL
and	NULL
full-length	NULL
protein	NULL
(	NULL
from	NULL
David	NULL
Kabat	NULL
,	NULL
Oregon	NULL
Health	NULL
Sciences	NULL
University	NULL
)	NULL
.	NULL

Bands	NULL
five	NULL
and	NULL
six	NULL
are	NULL
also	NULL
inhibited	NULL
by	NULL
competition	NULL
with	NULL
the	NULL
PU.1	NULL
oligonucleotide	NULL
(	NULL
-32	NULL
to	NULL
-1	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
in	NULL
an	NULL
investigation	NULL
of	NULL
the	NULL
nonconsensus	NULL
AP-1	NULL
site	NULL
,	NULL
bands	NULL
one	NULL
,	NULL
two	NULL
,	NULL
and	NULL
four	NULL
were	NULL
considered	NULL
.	NULL

Band	NULL
two	NULL
Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
cold	NULL
oligonucleotide	NULL
-32/+14	NULL
and	NULL
was	NULL
therefore	NULL
thought	NULL
to	NULL
be	NULL
nonspecific	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Neither	NULL
band	NULL
one	NULL
nor	NULL
band	NULL
four	NULL
was	NULL
supershifted	NULL
or	NULL
reduced	NULL
by	NULL
anti-pan-fos	NULL
or	NULL
anti-pan-jun	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

However	NULL
,	NULL
both	NULL
of	NULL
these	NULL
antibodies	NULL
affected	NULL
specific	NULL
AP-1-shifted	NULL
bands	NULL
detected	NULL
in	NULL
U937	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
by	NULL
using	NULL
a	NULL
consensus	NULL
metallothionein	NULL
AP-1	NULL
probe	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Bands	NULL
one	NULL
and	NULL
four	NULL
were	NULL
also	NULL
not	NULL
inhibited	NULL
upon	NULL
addition	NULL
of	NULL
a	NULL
cold	NULL
competitor	NULL
consensus	NULL
AP-1	NULL
oligonucleotide	NULL
from	NULL
the	NULL
metallothionein	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

We	NULL
concluded	NULL
that	NULL
the	NULL
diffuse	NULL
band	NULL
four	NULL
corresponds	NULL
to	NULL
the	NULL
nonspecific	NULL
band	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

7A	NULL
and	NULL
that	NULL
band	NULL
one	NULL
corresponds	NULL
to	NULL
a	NULL
protein	NULL
binding	NULL
FP4-3	NULL
'	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

We	NULL
also	NULL
concluded	NULL
that	NULL
AP-1	NULL
does	NULL
not	NULL
regulate	NULL
c-fes	NULL
.	NULL

PU.1	NULL
binds	NULL
to	NULL
the	NULL
c-fes	NULL
promoter	NULL
at	NULL
two	NULL
sites	NULL
,	NULL
-21	NULL
to	NULL
-14	NULL
and	NULL
-8	NULL
to	NULL
+3	NULL
.	NULL

A	NULL
recent	NULL
report	NULL
(	NULL
26	NULL
)	NULL
claims	NULL
that	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
binds	NULL
to	NULL
the	NULL
sequence	NULL
5-AATCAGGAACT-3	NULL
'	NULL
located	NULL
at	NULL
nucleotides	NULL
-8	NULL
to	NULL
+3	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
.	NULL

The	NULL
oligonucleotide	NULL
-32/+14	NULL
was	NULL
used	NULL
in	NULL
EMSAs	NULL
with	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
PU.1	NULL
binds	NULL
to	NULL
the	NULL
PU.1/	NULL
FPA4-3	NULL
'	NULL
(	NULL
-32/+14	NULL
)	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
is	NULL
specifically	NULL
inhibited	NULL
by	NULL
excess	NULL
cold	NULL
competitor	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
the	NULL
PU.1	NULL
oligonucleotide	NULL
(	NULL
-32	NULL
to	NULL
-1	NULL
)	NULL
also	NULL
competes	NULL
for	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
while	NULL
a	NULL
mutation	NULL
at	NULL
the	NULL
Ets	NULL
site	NULL
at	NULL
-21	NULL
no	NULL
longer	NULL
competes	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

This	NULL
demonstrates	NULL
that	NULL
the	NULL
-32/-1	NULL
oligonucleotide	NULL
does	NULL
not	NULL
include	NULL
the	NULL
complete	NULL
PU.1	NULL
site	NULL
from	NULL
-8	NULL
to	NULL
+3	NULL
.	NULL

Mutations	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
3	NULL
of	NULL
the	NULL
flanking	NULL
site	NULL
FPA4-3	NULL
'	NULL
(	NULL
-8	NULL
to	NULL
+3	NULL
)	NULL
competed	NULL
efficiently	NULL
in	NULL
our	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
lanes	NULL
8	NULL
to	NULL
10	NULL
)	NULL
,	NULL
showing	NULL
that	NULL
the	NULL
-21	NULL
site	NULL
is	NULL
intact	NULL
.	NULL

EMSAs	NULL
with	NULL
the	NULL
-11/+5	NULL
oligonucleotide	NULL
also	NULL
demonstrated	NULL
binding	NULL
of	NULL
PU.1	NULL
in	NULL
U937	NULL
nuclear	NULL
extracts	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

10A	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Because	NULL
both	NULL
the	NULL
-32/-1	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
and	NULL
the	NULL
-11/+5	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

10A	NULL
)	NULL
bind	NULL
efficiently	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
PU.1	NULL
binds	NULL
to	NULL
the	NULL
Ets	NULL
site	NULL
at	NULL
-21	NULL
and	NULL
to	NULL
the	NULL
site	NULL
at	NULL
-8	NULL
.	NULL

The	NULL
-32/+14	NULL
oligonucleotide	NULL
harbors	NULL
two	NULL
binding	NULL
sites	NULL
for	NULL
PU.1	NULL
in	NULL
addition	NULL
to	NULL
a	NULL
site	NULL
for	NULL
the	NULL
FP4-3	NULL
'	NULL
activity	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
myeloid-cell-specific	NULL
c-fes	NULL
promoter	NULL
by	NULL
PU.1	NULL
.	NULL

Given	NULL
the	NULL
specific	NULL
binding	NULL
of	NULL
both	NULL
Elf-1	NULL
and	NULL
PU.1	NULL
to	NULL
the	NULL
c-fes	NULL
promoter	NULL
,	NULL
we	NULL
performed	NULL
a	NULL
series	NULL
of	NULL
transient-cotransfection	NULL
experiments	NULL
with	NULL
both	NULL
of	NULL
these	NULL
proteins	NULL
in	NULL
the	NULL
nonmyeloid	NULL
Cos	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
lacks	NULL
endogenous	NULL
Elf-1	NULL
or	NULL
PU.1	NULL
activity	NULL
.	NULL

The	NULL
promoterless	NULL
luciferase	NULL
expression	NULL
vector	NULL
pGL2	NULL
,	NULL
a	NULL
minimal	NULL
c-fes	NULL
promoter	NULL
construct	NULL
(	NULL
p51	NULL
)	NULL
,	NULL
and	NULL
a	NULL
c-fes	NULL
promoter	NULL
construct	NULL
containing	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
Ets	NULL
site	NULL
(	NULL
pS1im	NULL
)	NULL
were	NULL
introduced	NULL
into	NULL
Cos	NULL
cells	NULL
with	NULL
expression	NULL
plasmids	NULL
that	NULL
produce	NULL
high	NULL
levels	NULL
of	NULL
Elf-1	NULL
or	NULL
PU.1	NULL
driven	NULL
by	NULL
the	NULL
cytomegalovirus	NULL
promoter	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
cotransfection	NULL
with	NULL
PU.1	NULL
resulted	NULL
in	NULL
a	NULL
reproducible	NULL
fivefold	NULL
stimulation	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
,	NULL
and	NULL
this	NULL
stimulation	NULL
was	NULL
dependent	NULL
on	NULL
having	NULL
the	NULL
-21	NULL
Ets	NULL
binding	NULL
site	NULL
intact	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
experiments	NULL
carried	NULL
out	NULL
with	NULL
3T3	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
PU.1	NULL
transactivated	NULL
constructs	NULL
containing	NULL
the	NULL
full	NULL
promoter	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
Elf-1	NULL
failed	NULL
to	NULL
transactivate	NULL
the	NULL
c-fes	NULL
promoter	NULL
in	NULL
either	NULL
cell	NULL
line	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
these	NULL
results	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
PU.1	NULL
is	NULL
the	NULL
most	NULL
likely	NULL
member	NULL
of	NULL
the	NULL
Ets	NULL
family	NULL
of	NULL
DNA-binding	NULL
proteins	NULL
to	NULL
regulate	NULL
c-fes	NULL
gene	NULL
expression	NULL
.	NULL

Furthermore	NULL
,	NULL
when	NULL
the	NULL
Ets	NULL
site	NULL
at	NULL
position	NULL
-21	NULL
is	NULL
mutated	NULL
,	NULL
PU.1	NULL
fails	NULL
to	NULL
transactivate	NULL
the	NULL
c-fes	NULL
promoter	NULL
even	NULL
though	NULL
the	NULL
PU.1	NULL
binding	NULL
site	NULL
at	NULL
-8	NULL
is	NULL
intact	NULL
.	NULL

A	NULL
novel	NULL
factor	NULL
binds	NULL
to	NULL
the	NULL
FP4-3	NULL
'	NULL
site	NULL
in	NULL
the	NULL
c-fes	NULL
promoter	NULL
.	NULL

Our	NULL
results	NULL
clearly	NULL
demonstrate	NULL
that	NULL
PU.1	NULL
binds	NULL
specifically	NULL
to	NULL
the	NULL
Ets	NULL
site	NULL
at	NULL
nucleotide	NULL
-21	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
and	NULL
that	NULL
transactivation	NULL
depends	NULL
on	NULL
the	NULL
integrity	NULL
of	NULL
the	NULL
-21	NULL
site	NULL
.	NULL

We	NULL
performed	NULL
EMSAs	NULL
to	NULL
determine	NULL
what	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
binds	NULL
to	NULL
FP4-3	NULL
'	NULL
(	NULL
-8	NULL
to	NULL
+3	NULL
)	NULL
,	NULL
having	NULL
determined	NULL
that	NULL
AP-1	NULL
does	NULL
not	NULL
bind	NULL
to	NULL
FPA4-3	NULL
'	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

These	NULL
EMSAs	NULL
utilized	NULL
a	NULL
shorter	NULL
oligonucle-	NULL
REGULATION	NULL
OF	NULL
c-fes	NULL
BY	NULL
A	NULL
NOVEL	NULL
TRANSCRIPTION	NULL
FACTOR	NULL
1683	NULL
Extract	NULL
:	NULL
'	NULL
IVT	NULL
PUA	NULL
leu	NULL
!	NULL

€	NULL
3	NULL
4	NULL
a	NULL
528	NULL
ee	NULL
£	NULL
no	NULL
n	NULL
g	NULL
§	NULL
5	NULL
8	NULL
oR	NULL
I	NULL
5	NULL
§	NULL
.	NULL

a	NULL
3	NULL
3	NULL
3	NULL
a	NULL
&	NULL
g	NULL
Competitor	NULL
:	NULL
-	NULL
3	NULL
2	NULL
Z	NULL
a	NULL
a	NULL
-	NULL
E	NULL
&	NULL
E	NULL
8	NULL
a	NULL
9	NULL
.	NULL

Antibody	NULL
:	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
.	NULL

-	NULL
-	NULL
>	NULL
«	NULL
-	NULL
--	NULL
vi	NULL
38	NULL
#	NULL
®	NULL
``	NULL
*	NULL
-p	NULL
ao	NULL
db	NULL
am	NULL
«	NULL
h	NULL
me	NULL
aik	NULL
am	NULL
wh	NULL
[	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
s	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
44	NULL
,	NULL
c-fes	NULL
-32/+14	NULL
Probe	NULL
:	NULL
$	NULL
SV40	NULL
PU.1	NULL
:	NULL
AAAGAGGAACTT	NULL
SVA40	NULL
mut	NULL
:	NULL
--	NULL
-C-CcGoc	NULL
--	NULL
-	NULL
PU.1/FP4-3	NULL
'	NULL
:	NULL
GAGGAGGAAGCGCGGAATCAGGAAC	NULL
Muti	NULL
:	NULL
--	NULL
~	NULL
--	NULL
--	NULL
--	NULL
--	NULL
-_._~-	NULL
CC-C	NULL
--	NULL
__-_	NULL
--	NULL
-Mut2	NULL
;	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
~_-_~-	NULL
cc-cGGé	NULL
--	NULL
--	NULL
-mut3	NULL
:	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
-	NULL
CCT-ATTAAGG-	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

EMSA	NULL
with	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
and	NULL
the	NULL
c-fes	NULL
-32/+14	NULL
oligonucleotide	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

Lanes	NULL
2	NULL
through	NULL
6	NULL
and	NULL
8	NULL
through	NULL
13	NULL
contain	NULL
the	NULL
indicated	NULL
cold	NULL
competitors	NULL
.	NULL

The	NULL
oligonucleotide	NULL
PU.1	NULL
is	NULL
from	NULL
bp	NULL
-32	NULL
to	NULL
-1	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
.	NULL

The	NULL
oligonucleotide	NULL
PU.1	NULL
mut	NULL
is	NULL
the	NULL
same	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

7A	NULL
.	NULL

Other	NULL
mutations	NULL
are	NULL
given	NULL
below	NULL
the	NULL
autoradiogram	NULL
.	NULL

The	NULL
numbers	NULL
in	NULL
lanes	NULL
2	NULL
and	NULL
11	NULL
through	NULL
13	NULL
represent	NULL
the	NULL
first	NULL
and	NULL
last	NULL
bases	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
,	NULL
which	NULL
correspond	NULL
to	NULL
the	NULL
oligonucleotides	NULL
used	NULL
as	NULL
cold	NULL
competitors	NULL
.	NULL

IVT	NULL
,	NULL
in	NULL
vitro	NULL
translated	NULL
;	NULL
RL	NULL
,	NULL
reticulocyte	NULL
lysate	NULL
.	NULL

Solid	NULL
arrows	NULL
,	NULL
DNA-protein	NULL
complexes	NULL
;	NULL
dashed	NULL
arrow	NULL
,	NULL
supershifted	NULL
complex	NULL
;	NULL
«	NULL
,	NULL
anti	NULL
.	NULL

otide	NULL
probe	NULL
(	NULL
-11	NULL
to	NULL
+5	NULL
)	NULL
in	NULL
order	NULL
to	NULL
isolate	NULL
the	NULL
FP4-3	NULL
'	NULL
binding	NULL
interaction	NULL
.	NULL

Figure	NULL
10A	NULL
shows	NULL
the	NULL
results	NULL
of	NULL
EMSAs	NULL
performed	NULL
to	NULL
determine	NULL
where	NULL
the	NULL
FP4-3	NULL
'	NULL
complex	NULL
binds	NULL
within	NULL
the	NULL
oligonucleotide	NULL
-11/+5	NULL
.	NULL

Lanes	NULL
1	NULL
through	NULL
5	NULL
of	NULL
Fig	NULL
.	NULL

10A	NULL
demonstrate	NULL
that	NULL
the	NULL
most	NULL
slowly	NULL
migrating	NULL
complex	NULL
corresponds	NULL
to	NULL
the	NULL
FP4-3	NULL
'	NULL
binding	NULL
activity	NULL
.	NULL

This	NULL
band	NULL
is	NULL
inhibited	NULL
by	NULL
the	NULL
wild-type	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

10A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
but	NULL
not	NULL
by	NULL
any	NULL
of	NULL
the	NULL
three	NULL
mutations	NULL
(	NULL
Fig	NULL
.	NULL

10A	NULL
,	NULL
lanes	NULL
3	NULL
through	NULL
5	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
FP4-3	NULL
'	NULL
site	NULL
that	NULL
affects	NULL
the	NULL
sequence	NULL
5-GAATCAGGAACT-3	NULL
'	NULL
(	NULL
mut1	NULL
)	NULL
interrupts	NULL
binding	NULL
and	NULL
decreases	NULL
¢-fes	NULL
expression	NULL
in	NULL
transient-transfection	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

This	NULL
mutation	NULL
still	NULL
allows	NULL
PU.1	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
-8	NULL
site	NULL
.	NULL

Lanes	NULL
6	NULL
,	NULL
7	NULL
,	NULL
and	NULL
10	NULL
of	NULL
Fig	NULL
.	NULL

10A	NULL
confirm	NULL
that	NULL
this	NULL
FP4-3'-protein	NULL
complex	NULL
does	NULL
not	NULL
contain	NULL
PU.1	NULL
.	NULL

Neither	NULL
a	NULL
consensus	NULL
PU.1	NULL
oligonucleotide	NULL
from	NULL
SV40	NULL
nor	NULL
a	NULL
PU.1	NULL
antibody	NULL
disrupts	NULL
the	NULL
FP4-3	NULL
'	NULL
complex	NULL
.	NULL

However	NULL
,	NULL
the	NULL
SV40	NULL
PU.1	NULL
oligonucleotide	NULL
specifically	NULL
inhibits	NULL
the	NULL
PU.1	NULL
complex	NULL
(	NULL
the	NULL
fastest	NULL
two	NULL
bands	NULL
in	NULL
Fig	NULL
.	NULL

10A	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
FP4-3	NULL
'	NULL
is	NULL
not	NULL
affected	NULL
by	NULL
Spl	NULL
or	NULL
AP-1	NULL
oligonucleotides	NULL
or	NULL
by	NULL
antibodies	NULL
to	NULL
PU.1	NULL
,	NULL
Myb	NULL
,	NULL
Elf-1	NULL
,	NULL
Fos	NULL
,	NULL
or	NULL
Jun	NULL
(	NULL
Fig	NULL
.	NULL

10A	NULL
,	NULL
lanes	NULL
8	NULL
through	NULL
14	NULL
)	NULL
.	NULL

1684	NULL
HEYDEMANN	NULL
ET	NULL
AL	NULL
.	NULL

Mean	NULL
Value	NULL
Fold	NULL
RLU/ng	NULL
Increase	NULL
GL2	NULL
=	NULL
956	NULL
1.0	NULL
P	NULL
|	NULL
:	NULL
+	NULL
PU1	NULL
1099	NULL
1.15	NULL
-	NULL
1113	NULL
1.0	NULL
p51	NULL
I	NULL
:	NULL
+	NULL
PU.1	NULL
5596	NULL
5.0	NULL
+	NULL
EIf-1	NULL
1026	NULL
0.92	NULL
=	NULL
1488	NULL
1.0	NULL
pSim	NULL
+	NULL
PU.1	NULL
1261	NULL
0.85	NULL
+	NULL
Elf-1	NULL
1118	NULL
0.75	NULL
o	NULL
-	NULL
]	NULL
&	NULL
-l	NULL
&	NULL
o	NULL
o	NULL
&	NULL
o	NULL
&	NULL
©	NULL
-	NULL
&	NULL
S	NULL
§	NULL
s	NULL
§	NULL
f	NULL
|	NULL
Promoter	NULL
Activity	NULL
Relative	NULL
Light	NULL
Units/ng	NULL
Growth	NULL
Hormone	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

Cotransfection	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
into	NULL
Cos	NULL
cells	NULL
with	NULL
peDNA-PU.1	NULL
and	NULL
pcDNA-Elf-1	NULL
.	NULL

Four	NULL
micrograms	NULL
of	NULL
each	NULL
of	NULL
the	NULL
indicated	NULL
c-fes	NULL
plasmids	NULL
was	NULL
lipofected	NULL
into	NULL
Cos	NULL
cells	NULL
along	NULL
with	NULL
16	NULL
pg	NULL
of	NULL
cither	NULL
peDNA-PU.1	NULL
or	NULL
peDNA-Elf-1	NULL
.	NULL

p51m	NULL
is	NULL
a	NULL
c-fes	NULL
plasmid	NULL
that	NULL
is	NULL
identical	NULL
to	NULL
p51	NULL
except	NULL
that	NULL
the	NULL
PU.1	NULL
binding	NULL
site	NULL
has	NULL
been	NULL
mutated	NULL
to	NULL
the	NULL
site	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Control	NULL
experiments	NULL
included	NULL
16	NULL
pg	NULL
of	NULL
empty	NULL
pcDNA	NULL
construct	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
2	NULL
pg	NULL
of	NULL
pCMV-GH	NULL
was	NULL
included	NULL
to	NULL
normalize	NULL
lipofection	NULL
efficiencies	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
tissue	NULL
distribution	NULL
of	NULL
the	NULL
FP4-3	NULL
'	NULL
-binding	NULL
factor	NULL
,	NULL
EMSAs	NULL
were	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
myeloid	NULL
(	NULL
U937	NULL
,	NULL
THP-1	NULL
,	NULL
HL60	NULL
,	NULL
K562	NULL
,	NULL
and	NULL
KG1	NULL
)	NULL
and	NULL
nonmyeloid	NULL
(	NULL
HepG2	NULL
,	NULL
Jurkat	NULL
,	NULL
Clone	NULL
13	NULL
,	NULL
and	NULL
HeLa	NULL
)	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
.	NULL

10B	NULL
)	NULL
.	NULL

The	NULL
FP4-3'-specific	NULL
complex	NULL
was	NULL
present	NULL
only	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
myeloid	NULL
cell	NULL
line	NULL
,	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
HepG2	NULL
liver	NULL
cells	NULL
,	NULL
which	NULL
also	NULL
contain	NULL
the	NULL
activity	NULL
.	NULL

The	NULL
slowly	NULL
migrating	NULL
complex	NULL
was	NULL
not	NULL
detected	NULL
in	NULL
Jurkat	NULL
T-cell	NULL
,	NULL
Clone	NULL
13	NULL
B-cell	NULL
,	NULL
or	NULL
HeLa	NULL
epithelial-cell	NULL
nuclear	NULL
extracts	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
the	NULL
FP4-3	NULL
'	NULL
complex	NULL
is	NULL
largely	NULL
restricted	NULL
to	NULL
myeloid	NULL
cells	NULL
.	NULL

DISCUSSION	NULL
The	NULL
c-fes	NULL
tyrosine	NULL
kinase	NULL
appears	NULL
to	NULL
be	NULL
highly	NULL
restricted	NULL
in	NULL
its	NULL
pattern	NULL
of	NULL
expression	NULL
in	NULL
adult	NULL
mammals	NULL
.	NULL

Although	NULL
it	NULL
is	NULL
expressed	NULL
in	NULL
other	NULL
tissues	NULL
in	NULL
murine	NULL
and	NULL
human	NULL
embryos	NULL
,	NULL
after	NULL
birth	NULL
it	NULL
is	NULL
detected	NULL
only	NULL
in	NULL
cells	NULL
of	NULL
the	NULL
myeloid	NULL
lineage	NULL
(	NULL
mono-cytes	NULL
and	NULL
neutrophils	NULL
and	NULL
their	NULL
precursors	NULL
)	NULL
and	NULL
in	NULL
vascular	NULL
endothelial	NULL
cells	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
evidence	NULL
strongly	NULL
implicate	NULL
the	NULL
c-fes	NULL
protein	NULL
as	NULL
being	NULL
crucial	NULL
for	NULL
monocytic	NULL
and	NULL
neutrophilic	NULL
development	NULL
:	NULL
increased	NULL
levels	NULL
of	NULL
kinase	NULL
activity	NULL
correlate	NULL
with	NULL
the	NULL
maturation	NULL
of	NULL
monocytes	NULL
and	NULL
neutrophils	NULL
(	NULL
31	NULL
,	NULL
38	NULL
)	NULL
,	NULL
and	NULL
inhibition	NULL
of	NULL
c-fes	NULL
mRNA	NULL
translation	NULL
into	NULL
protein	NULL
leads	NULL
to	NULL
apoptotic	NULL
death	NULL
during	NULL
neutrophilic	NULL
differentiation	NULL
(	NULL
8	NULL
,	NULL
20	NULL
)	NULL
.	NULL

Re	NULL
B	NULL
&	NULL
Extract	NULL
:	NULL
!	NULL

U9sr	NULL
~A	NULL
no	NULL
-T	NULL
o	NULL
a	NULL
8	NULL
#	NULL
2	NULL
©	NULL
&	NULL
©	NULL
©	NULL
L	NULL
a	NULL
£	NULL
§	NULL
J	NULL
Io	NULL
o	NULL
I	NULL
J	NULL
m	NULL
0	NULL
0	NULL
3	NULL
2	NULL
o	NULL
2:5	NULL
:	NULL
Extract	NULL
:	NULL
35	NULL
-	NULL
IE	NULL
¥	NULL
¥	NULL
I	NULL
53	NULL
O	NULL
T	NULL
2	NULL
-	NULL
a	NULL
m	NULL
9	NULL
9	NULL
+-Competitor	NULL
:	NULL
-	NULL
u	NULL
§	NULL
§	NULL
§	NULL
$	NULL
$	NULL
o	NULL
og	NULL
[	NULL
-	NULL
-	NULL
-	NULL
-	NULL
pe	NULL
c	NULL
f	NULL
E	NULL
f	NULL
a	NULL
a	NULL
&	NULL
%	NULL
Lo	NULL
€	NULL
Loe	NULL
g	NULL
R	NULL
5	NULL
2	NULL
«	NULL
#	NULL
Antibody	NULL
:	NULL
L	NULL
.	NULL

0.	NULL
l.	NULL
c.	NULL
c.	NULL
l.	NULL
.	NULL

.	NULL

a	NULL
$	NULL
&	NULL
2	NULL
5	NULL
to	NULL
d	NULL
5	NULL
5	NULL
58	NULL
FPA-3	NULL
'	NULL
-	NULL
»	NULL
-	NULL
‘	NULL
S	NULL
po-	NULL
-	NULL
.-FP4-3	NULL
'	NULL
-	NULL
»	NULL
@	NULL
t	NULL
an	NULL
«	NULL
»	NULL
@	NULL
p	NULL
«	NULL
»	NULL
«	NULL
»	NULL
...	NULL
..	NULL
“	NULL
PU	NULL
.	NULL

1	NULL
-	NULL
»	NULL
PU	NULL
.	NULL

1	NULL
-	NULL
»	NULL
*~*	NULL
*-	NULL
»	NULL
sie	NULL
[	NULL
1020	NULL
380	NULL
4	NULL
5	NULL
60	NULL
7080	NULL
9	NULL
do	NULL
11	NULL
121314	NULL
[	NULL
1020	NULL
8	NULL
4	NULL
5	NULL
6	NULL
7	NULL
O8	NULL
9	NULL
,	NULL
Probe	NULL
:	NULL
c-fes	NULL
11/+5	NULL
Probe	NULL
:	NULL
o-fes	NULL
11/15	NULL
c-fes	NULL
-11/+5	NULL
:	NULL
CGGAATCAGGAACTGG	NULL
PU.1/FP4-3	NULL
'	NULL
:	NULL
GAGGAGGARGCGCGGAATCAGCAACTGG	NULL
muti	NULL
:	NULL
--	NULL
--	NULL
--	NULL
--	NULL
-_-_	NULL
--	NULL
--	NULL
CC-C	NULL
--	NULL
_______-MUut2	NULL
:	NULL
<	NULL
--	NULL
--	NULL
--	NULL
--	NULL
_-_	NULL
--	NULL
--	NULL
cc-céé	NULL
--	NULL
--	NULL
--	NULL
--	NULL
mutd	NULL
:	NULL
--	NULL
--	NULL
--	NULL
--	NULL
~-_-~~-	NULL
CCT-ATTAAGG	NULL
--	NULL
--	NULL
SV40	NULL
PU.1	NULL
:	NULL
AAAGAGGAACTT	NULL
SV40	NULL
mut	NULL
:	NULL
--	NULL
-c-ccGs	NULL
--	NULL
-	NULL
FIG	NULL
.	NULL

10	NULL
.	NULL

Location	NULL
of	NULL
the	NULL
FP4-3	NULL
'	NULL
site-protein	NULL
complex	NULL
on	NULL
oligonucleotide	NULL
-11/+5	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSA	NULL
with	NULL
U937	NULL
nuclear	NULL
extracts	NULL
and	NULL
the	NULL
c-fes	NULL
-11/+5	NULL
probe	NULL
.	NULL

Lanes	NULL
2	NULL
through	NULL
9	NULL
contain	NULL
100	NULL
ng	NULL
of	NULL
the	NULL
indicated	NULL
cold	NULL
competitor	NULL
oligonucleotide	NULL
.	NULL

Lanes	NULL
10	NULL
through	NULL
14	NULL
contain	NULL
the	NULL
indicated	NULL
antibodies	NULL
.	NULL

Mutations	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
3	NULL
were	NULL
tested	NULL
in	NULL
competing	NULL
oligonucleotides	NULL
including	NULL
bp	NULL
-32	NULL
to	NULL
+14	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
c-fes	NULL
-11/+5	NULL
probe	NULL
was	NULL
used	NULL
with	NULL
the	NULL
various	NULL
indicated	NULL
nuclear	NULL
extracts	NULL
.	NULL

Solid	NULL
arrows	NULL
,	NULL
DNA-protein	NULL
complexes	NULL
;	NULL
asterisk	NULL
,	NULL
proteolyzed	NULL
PU.1	NULL
;	NULL
«	NULL
,	NULL
anti-	NULL
.	NULL

Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
markably	NULL
,	NULL
important	NULL
cis-acting	NULL
DNA	NULL
elements	NULL
that	NULL
ensure	NULL
high	NULL
levels	NULL
of	NULL
c-fes	NULL
transcription	NULL
in	NULL
myeloid	NULL
cells	NULL
must	NULL
reside	NULL
within	NULL
a	NULL
relatively	NULL
short	NULL
fragment	NULL
of	NULL
DNA	NULL
:	NULL
a	NULL
13-kb	NULL
human	NULL
transgene	NULL
is	NULL
expressed	NULL
in	NULL
the	NULL
appropriate	NULL
tissues	NULL
at	NULL
very	NULL
high	NULL
levels	NULL
.	NULL

The	NULL
reasons	NULL
for	NULL
our	NULL
interest	NULL
in	NULL
the	NULL
c-fes	NULL
gene	NULL
are	NULL
many	NULL
.	NULL

We	NULL
want	NULL
to	NULL
learn	NULL
which	NULL
proteins	NULL
are	NULL
responsible	NULL
for	NULL
tightly	NULL
controlling	NULL
c-fes	NULL
mRNA	NULL
production	NULL
.	NULL

If	NULL
c-fes	NULL
kinase	NULL
levels	NULL
are	NULL
critical	NULL
for	NULL
myeloid	NULL
development	NULL
,	NULL
it	NULL
stands	NULL
to	NULL
reason	NULL
that	NULL
the	NULL
factors	NULL
controlling	NULL
its	NULL
transcription	NULL
will	NULL
also	NULL
be	NULL
important	NULL
in	NULL
development	NULL
.	NULL

Also	NULL
,	NULL
a	NULL
potent	NULL
promoter	NULL
for	NULL
the	NULL
myeloid	NULL
lineage	NULL
will	NULL
be	NULL
a	NULL
useful	NULL
tool	NULL
for	NULL
the	NULL
generation	NULL
of	NULL
transgenic	NULL
mice	NULL
that	NULL
inappropriately	NULL
express	NULL
gene	NULL
products	NULL
in	NULL
these	NULL
lineages	NULL
.	NULL

Given	NULL
the	NULL
extremely	NULL
high	NULL
levels	NULL
of	NULL
expression	NULL
reported	NULL
for	NULL
a	NULL
13-kb	NULL
human	NULL
genomic	NULL
fragment	NULL
upon	NULL
introduction	NULL
into	NULL
transgenic	NULL
mice	NULL
,	NULL
we	NULL
reasoned	NULL
that	NULL
it	NULL
should	NULL
be	NULL
relatively	NULL
important	NULL
to	NULL
identify	NULL
cis-acting	NULL
sites	NULL
within	NULL
this	NULL
short	NULL
region	NULL
of	NULL
genomic	NULL
DNA	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
that	NULL
promoter-proximal	NULL
sequences	NULL
from	NULL
-151	NULL
to	NULL
+71	NULL
are	NULL
sufficient	NULL
to	NULL
direct	NULL
myeloid-cell-specific	NULL
expression	NULL
.	NULL

The	NULL
elements	NULL
that	NULL
appear	NULL
to	NULL
be	NULL
the	NULL
most	NULL
important	NULL
for	NULL
activity	NULL
during	NULL
electroporation	NULL
into	NULL
U937	NULL
cells	NULL
are	NULL
located	NULL
at	NULL
nucleotides	NULL
-99	NULL
to	NULL
-51	NULL
and	NULL
-34	NULL
to	NULL
+3	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
-99	NULL
region	NULL
selectively	NULL
binds	NULL
the	NULL
transcription	NULL
factor	NULL
Spl	NULL
.	NULL

The	NULL
footprinted	NULL
site	NULL
at	NULL
-34	NULL
includes	NULL
a	NULL
consensus	NULL
site	NULL
for	NULL
Ets	NULL
family	NULL
members	NULL
PU.1	NULL
and/or	NULL
Elf-1	NULL
as	NULL
opposed	NULL
to	NULL
Ets-1	NULL
.	NULL

Although	NULL
both	NULL
PU.1	NULL
and	NULL
Elf-1	NULL
recognize	NULL
this	NULL
site	NULL
in	NULL
in	NULL
vitro	NULL
binding	NULL
reactions	NULL
,	NULL
PU.1	NULL
alone	NULL
can	NULL
transactivate	NULL
the	NULL
c-fes	NULL
promoter	NULL
in	NULL
nonmyeloid	NULL
cell	NULL
lines	NULL
(	NULL
Cos	NULL
and	NULL
3T	NULL
3	NULL
cells	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
PU.1	NULL
is	NULL
the	NULL
critical	NULL
regulator	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
.	NULL

Furthermore	NULL
,	NULL
macrophages	NULL
that	NULL
lack	NULL
Elf-1	NULL
(	NULL
because	NULL
of	NULL
gene	NULL
tar-geting	NULL
)	NULL
still	NULL
express	NULL
normal	NULL
levels	NULL
of	NULL
c-fes	NULL
(	NULL
2a	NULL
)	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
mice	NULL
deficient	NULL
in	NULL
PU.1	NULL
do	NULL
not	NULL
produce	NULL
mature	NULL
macrophages	NULL
and	NULL
neutrophils	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
blockage	NULL
of	NULL
macrophage	NULL
and	NULL
neutrophil	NULL
development	NULL
is	NULL
coincident	NULL
with	NULL
c-fes	NULL
expression	NULL
in	NULL
these	NULL
lineages	NULL
.	NULL

We	NULL
have	NULL
isolated	NULL
early	NULL
myeloid	NULL
cells	NULL
lacking	NULL
PU.1	NULL
and	NULL
demonstrated	NULL
a	NULL
deficiency	NULL
in	NULL
c-fes	NULL
expression	NULL
(	NULL
Z21a	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
our	NULL
genetic	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
transactivation	NULL
results	NULL
showing	NULL
that	NULL
PU.1	NULL
is	NULL
the	NULL
Ets	NULL
family	NULL
member	NULL
that	NULL
regulates	NULL
c-fes	NULL
.	NULL

PU.1	NULL
has	NULL
been	NULL
proposed	NULL
as	NULL
a	NULL
regulator	NULL
of	NULL
other	NULL
myeloid-cell-specific	NULL
genes	NULL
,	NULL
including	NULL
CD11b	NULL
(	NULL
23	NULL
)	NULL
,	NULL
the	NULL
M-CSF	NULL
receptor	NULL
(	NULL
41	NULL
)	NULL
,	NULL
and	NULL
the	NULL
macrophage	NULL
scavenger	NULL
receptor	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
as	NULL
is	NULL
the	NULL
case	NULL
for	NULL
CD11b	NULL
and	NULL
the	NULL
M-CSF	NULL
receptor	NULL
,	NULL
PU.1	NULL
binds	NULL
to	NULL
a	NULL
site	NULL
just	NULL
5	NULL
'	NULL
of	NULL
the	NULL
primary	NULL
transcriptional	NULL
start	NULL
site	NULL
in	NULL
the	NULL
c-fes	NULL
promoter	NULL
,	NULL
which	NULL
also	NULL
lacks	NULL
a	NULL
consensus	NULL
TATA	NULL
box	NULL
.	NULL

Given	NULL
the	NULL
finding	NULL
that	NULL
PU.1	NULL
binds	NULL
to	NULL
TATA-binding	NULL
protein	NULL
in	NULL
vitro	NULL
(	NULL
12	NULL
)	NULL
,	NULL
it	NULL
is	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
PU.1	NULL
may	NULL
function	NULL
to	NULL
recruit	NULL
TFIID	NULL
and	NULL
then	NULL
the	NULL
other	NULL
components	NULL
of	NULL
the	NULL
basal	NULL
transcriptional	NULL
machinery	NULL
to	NULL
all	NULL
three	NULL
of	NULL
these	NULL
promoters	NULL
.	NULL

The	NULL
footprinted	NULL
promoter-proximal	NULL
region	NULL
from	NULL
-34	NULL
to	NULL
+3	NULL
also	NULL
includes	NULL
a	NULL
weak	NULL
consensus	NULL
site	NULL
for	NULL
AP-1	NULL
family	NULL
members	NULL
that	NULL
is	NULL
directly	NULL
adjacent	NULL
to	NULL
the	NULL
Ets	NULL
site	NULL
.	NULL

Many	NULL
Ets	NULL
family	NULL
transcription	NULL
factors	NULL
interact	NULL
with	NULL
another	NULL
protein	NULL
when	NULL
binding	NULL
to	NULL
DNA	NULL
(	NULL
4	NULL
,	NULL
9	NULL
,	NULL
34	NULL
)	NULL
.	NULL

Combinatorial	NULL
interactions	NULL
between	NULL
Ets-2	NULL
and	NULL
AP-1	NULL
for	NULL
the	NULL
scavenger	NULL
receptor	NULL
promoter	NULL
(	NULL
37	NULL
)	NULL
and	NULL
between	NULL
Elf-1	NULL
and	NULL
AP-1	NULL
for	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
(	NULL
34	NULL
)	NULL
have	NULL
been	NULL
described	NULL
.	NULL

PU.1	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
form	NULL
a	NULL
complex	NULL
with	NULL
the	NULL
B-cell	NULL
factor	NULL
NF-EMS	NULL
to	NULL
activate	NULL
the	NULL
immunoglobulin	NULL
k	NULL
and	NULL
\	NULL
3	NULL
'	NULL
enhancers	NULL
(	NULL
24	NULL
)	NULL
.	NULL

However	NULL
,	NULL
EMSAs	NULL
performed	NULL
with	NULL
the	NULL
PU.1	NULL
site	NULL
in	NULL
the	NULL
c-fes	NULL
promoter	NULL
failed	NULL
to	NULL
detect	NULL
PU.1	NULL
in	NULL
a	NULL
stable	NULL
complex	NULL
with	NULL
another	NULL
protein	NULL
.	NULL

A	NULL
distinct	NULL
assay	NULL
for	NULL
protein-DNA	NULL
interactions	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
DNase	NULL
I	NULL
footprinting	NULL
)	NULL
clearly	NULL
showed	NULL
that	NULL
both	NULL
the	NULL
PU.1	NULL
and	NULL
FP4-3	NULL
'	NULL
sites	NULL
bound	NULL
nuclear	NULL
proteins	NULL
in	NULL
U937	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
both	NULL
sites	NULL
are	NULL
functionally	NULL
important	NULL
for	NULL
c-fes	NULL
promoter	NULL
activity	NULL
in	NULL
U937	NULL
cells	NULL
.	NULL

It	NULL
seems	NULL
possible	NULL
that	NULL
a	NULL
PU.1/FP4-3'-protein	NULL
interaction	NULL
,	NULL
while	NULL
important	NULL
to	NULL
the	NULL
regulation	NULL
of	NULL
c-fes	NULL
expression	NULL
,	NULL
may	NULL
not	NULL
be	NULL
suffi-	NULL
REGULATION	NULL
OF	NULL
c-fes	NULL
BY	NULL
A	NULL
NOVEL	NULL
TRANSCRIPTION	NULL
FACTOR	NULL
1685	NULL
ciently	NULL
stable	NULL
in	NULL
a	NULL
gel	NULL
assay	NULL
for	NULL
detection	NULL
.	NULL

It	NULL
is	NULL
clear	NULL
that	NULL
the	NULL
FP4-3	NULL
'	NULL
site	NULL
(	NULL
5'-GAATCAGGAACT-3	NULL
'	NULL
)	NULL
does	NULL
not	NULL
bind	NULL
either	NULL
of	NULL
the	NULL
other	NULL
myeloid	NULL
transcription	NULL
factors	NULL
c-myb	NULL
(	NULL
5'-CAAC	NULL
GG-3	NULL
'	NULL
)	NULL
and	NULL
CEBP/a	NULL
«	NULL
(	NULL
5'-GTGGAAAG-3	NULL
'	NULL
)	NULL
,	NULL
as	NULL
their	NULL
consensus	NULL
sites	NULL
are	NULL
distinct	NULL
from	NULL
FP4-3	NULL
'	NULL
(	NULL
21	NULL
)	NULL
and	NULL
FP4-3	NULL
'	NULL
does	NULL
not	NULL
bind	NULL
antibodies	NULL
specific	NULL
for	NULL
myb	NULL
.	NULL

While	NULL
this	NULL
work	NULL
was	NULL
in	NULL
progress	NULL
,	NULL
Ray-Gallet	NULL
et	NULL
al	NULL
.	NULL

reported	NULL
that	NULL
PU.1	NULL
binds	NULL
to	NULL
the	NULL
c-fes	NULL
promoter	NULL
(	NULL
26	NULL
)	NULL
.	NULL

However	NULL
,	NULL
their	NULL
analyses	NULL
suggested	NULL
that	NULL
PU.1	NULL
binds	NULL
to	NULL
a	NULL
site	NULL
located	NULL
at	NULL
-8	NULL
to	NULL
+3	NULL
of	NULL
the	NULL
promoter	NULL
.	NULL

The	NULL
oligonucleotide	NULL
used	NULL
for	NULL
EMSAs	NULL
in	NULL
that	NULL
report	NULL
did	NULL
not	NULL
include	NULL
the	NULL
PU.1	NULL
site	NULL
that	NULL
we	NULL
have	NULL
identified	NULL
and	NULL
would	NULL
therefore	NULL
fail	NULL
to	NULL
detect	NULL
PU.1	NULL
binding	NULL
at	NULL
bp	NULL
-21	NULL
of	NULL
the	NULL
c-fes	NULL
promoter	NULL
.	NULL

The	NULL
-8	NULL
site	NULL
overlaps	NULL
the	NULL
FP4-3	NULL
'	NULL
site	NULL
,	NULL
which	NULL
is	NULL
located	NULL
at	NULL
-9	NULL
to	NULL
+3	NULL
and	NULL
for	NULL
which	NULL
we	NULL
have	NULL
demonstrated	NULL
specific	NULL
binding	NULL
of	NULL
a	NULL
novel	NULL
factor	NULL
.	NULL

Through	NULL
our	NULL
mutational	NULL
analysis	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
a	NULL
slowly	NULL
migrating	NULL
complex	NULL
corresponding	NULL
to	NULL
a	NULL
protein-DNA	NULL
interaction	NULL
at	NULL
FP4-3	NULL
'	NULL
which	NULL
is	NULL
critical	NULL
for	NULL
promoter	NULL
function	NULL
(	NULL
Fig	NULL
.	NULL

10B	NULL
)	NULL
.	NULL

This	NULL
band	NULL
is	NULL
not	NULL
supershifted	NULL
or	NULL
reduced	NULL
by	NULL
anti-PU.1	NULL
or	NULL
by	NULL
anti-Elf-1	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
FP4	NULL
includes	NULL
two	NULL
binding	NULL
sites	NULL
for	NULL
PU.1	NULL
in	NULL
addition	NULL
to	NULL
FP4-3	NULL
'	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
that	NULL
the	NULL
Sp1	NULL
,	NULL
PU.1	NULL
,	NULL
and	NULL
FP4-3	NULL
'	NULL
sites	NULL
have	NULL
been	NULL
conserved	NULL
in	NULL
the	NULL
chicken	NULL
,	NULL
feline	NULL
,	NULL
and	NULL
human	NULL
¢c-fes	NULL
promoters	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
FP4-3	NULL
'	NULL
complex	NULL
appears	NULL
to	NULL
contain	NULL
a	NULL
DNA	NULL
binding	NULL
activity	NULL
restricted	NULL
in	NULL
its	NULL
expression	NULL
to	NULL
myeloid	NULL
cells	NULL
.	NULL

It	NULL
will	NULL
be	NULL
of	NULL
interest	NULL
to	NULL
identify	NULL
the	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
binding	NULL
to	NULL
FPA4-3	NULL
'	NULL
that	NULL
regulates	NULL
c-fes	NULL
in	NULL
myeloid	NULL
cells	NULL
.	NULL

Such	NULL
a	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
could	NULL
be	NULL
useful	NULL
for	NULL
the	NULL
further	NULL
analysis	NULL
of	NULL
myeloid-cell-specific	NULL
expression	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Gail	NULL
Hubbard	NULL
for	NULL
her	NULL
careful	NULL
preparation	NULL
of	NULL
the	NULL
manu-script	NULL
.	NULL

This	NULL
research	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
NIH	NULL
(	NULL
HL52094-01	NULL
)	NULL
to	NULL
M.C.S	NULL
.	NULL

A.H.	NULL
is	NULL
supported	NULL
by	NULL
a	NULL
training	NULL
grant	NULL
to	NULL
the	NULL
University	NULL
of	NULL
Chicago	NULL
Cancer	NULL
Center	NULL
.	NULL

M.C.S	NULL
.	NULL

is	NULL
an	NULL
Investigator	NULL
of	NULL
the	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Alcalay	NULL
,	NULL
M.	NULL
,	NULL
W.	NULL
Antolini	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

Van	NULL
de	NULL
Ven	NULL
,	NULL
L.	NULL
Lanfrancone	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
and	NULL
P.	NULL
Pelicci	NULL
.	NULL

1990	NULL
.	NULL

Characterization	NULL
of	NULL
human	NULL
and	NULL
mouse	NULL
c-fes	NULL
cDNA	NULL
clones	NULL
and	NULL
identification	NULL
of	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
gene	NULL
.	NULL

Oncogene	NULL
5:267-275	NULL
.	NULL

2	NULL
.	NULL

Andrews	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
D.	NULL
Faller	NULL
,	NULL
1991	NULL
.	NULL

Rapid	NULL
micropreparation	NULL
technique	NULL
for	NULL
extraction	NULL
of	NULL
DNA-binding	NULL
proteins	NULL
from	NULL
limiting	NULL
numbers	NULL
of	NULL
mammalian	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:2499	NULL
.	NULL

2a.Barton	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
Olson	NULL
,	NULL
M.	NULL
C.	NULL
Simon	NULL
,	NULL
and	NULL
J.	NULL
Leiden	NULL
.	NULL

Unpublished	NULL
observations	NULL
.	NULL

2b.Bassuk	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
J.	NULL
Leiden	NULL
.	NULL

Unpublished	NULL
observations	NULL
.	NULL

3	NULL
.	NULL

Care	NULL
,	NULL
A.	NULL
,	NULL
G.	NULL
Mattia	NULL
,	NULL
E.	NULL
Montesoro	NULL
,	NULL
I.	NULL
Parolini	NULL
,	NULL
G.	NULL
Russo	NULL
,	NULL
M.	NULL
Colombo	NULL
,	NULL
and	NULL
C.	NULL
Peschle	NULL
.	NULL

1994.	NULL
c-fes	NULL
expression	NULL
in	NULL
ontogenetic	NULL
development	NULL
and	NULL
hematopoictic	NULL
differentiation	NULL
.	NULL

Oncogene	NULL
9:739-747	NULL
.	NULL

4	NULL
.	NULL

Dalton	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
R.	NULL
Treisman	NULL
.	NULL

1992	NULL
.	NULL

Characterization	NULL
of	NULL
SAP-1	NULL
,	NULL
a	NULL
protein	NULL
recruited	NULL
by	NULL
serum	NULL
response	NULL
factor	NULL
to	NULL
the	NULL
c-fos	NULL
serum	NULL
response	NULL
element	NULL
.	NULL

Cell	NULL
68:597-612	NULL
.	NULL

5	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
,	NULL
R.	NULL
Lebovitz	NULL
,	NULL
and	NULL
R.	NULL
Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475-1489	NULL
.	NULL

6	NULL
.	NULL

Dynan	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1983	NULL
.	NULL

The	NULL
promoter-specific	NULL
transcription	NULL
factor	NULL
Sp-1	NULL
binds	NULL
to	NULL
upstream	NULL
sequences	NULL
in	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
.	NULL

Cell	NULL
35:79-87	NULL
.	NULL

7	NULL
.	NULL

Feldman	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
Gabrilove	NULL
,	NULL
J.	NULL
Tam	NULL
,	NULL
M.	NULL
Moore	NULL
,	NULL
and	NULL
H.	NULL
Hanafusa	NULL
.	NULL

1985	NULL
.	NULL

Specific	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
cellular	NULL
fps/fes-encoded	NULL
protein	NULL
NCP92	NULL
in	NULL
normal	NULL
and	NULL
leukemic	NULL
myeloid	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:2379-2383	NULL
.	NULL

8	NULL
.	NULL

Ferrari	NULL
,	NULL
S.	NULL
,	NULL
A.	NULL
Donelli	NULL
,	NULL
R.	NULL
Manfredini	NULL
,	NULL
M.	NULL
Sarti	NULL
,	NULL
R.	NULL
Roncaglia	NULL
,	NULL
E.	NULL
Tagliafico	NULL
,	NULL
E.	NULL
Rossi	NULL
,	NULL
G.	NULL
Torelli	NULL
,	NULL
and	NULL
U.	NULL
Torelli	NULL
.	NULL

1990	NULL
.	NULL

Differential	NULL
effects	NULL
of	NULL
c-myb	NULL
and	NULL
¢-fes	NULL
antisense	NULL
oligodeoxynucleotides	NULL
on	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
human	NULL
myeloid	NULL
leukemia	NULL
HL6O	NULL
cells	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

548:543-548	NULL
.	NULL

9	NULL
.	NULL

Gottschalk	NULL
,	NULL
L.	NULL
,	NULL
D.	NULL
Giannola	NULL
,	NULL
and	NULL
S.	NULL
Emerson	NULL
.	NULL

1993	NULL
.	NULL

Molecular	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
IL-3	NULL
gene	NULL
:	NULL
inducible	NULL
T	NULL
cell-restricted	NULL
expression	NULL
requires	NULL
intact	NULL
AP-1	NULL
and	NULL
Elf-1	NULL
nuclear	NULL
protein	NULL
binding	NULL
sites	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:1681-1692	NULL
.	NULL

10	NULL
.	NULL

Greer	NULL
,	NULL
P.	NULL
,	NULL
J.	NULL
Haigh	NULL
,	NULL
G.	NULL
Mbamalu	NULL
,	NULL
W.	NULL
Khoo	NULL
,	NULL
A.	NULL
Bernstein	NULL
,	NULL
and	NULL
T.	NULL
Pawson	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
Fps/Fes	NULL
protein-tyrosine	NULL
kinase	NULL
promotes	NULL
angiogenesis	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:6755-6763	NULL
.	NULL

11	NULL
.	NULL

Greer	NULL
,	NULL
P.	NULL
,	NULL
V.	NULL
Maltby	NULL
,	NULL
J.	NULL
Rossant	NULL
,	NULL
A.	NULL
Bernstein	NULL
,	NULL
and	NULL
T.	NULL
Pawson	NULL
.	NULL

1990	NULL
.	NULL

Myeloid	NULL
1686	NULL
12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

HEYDEMANN	NULL
ET	NULL
AL	NULL
.	NULL

expression	NULL
of	NULL
the	NULL
human	NULL
¢-fps/fes	NULL
proto-oncogene	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:2521-2527	NULL
.	NULL

Hagemeier	NULL
,	NULL
C.	NULL
,	NULL
A.	NULL
Bannister	NULL
,	NULL
A.	NULL
Cook	NULL
,	NULL
and	NULL
T.	NULL
Kouzarides	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
activation	NULL
domain	NULL
of	NULL
transcription	NULL
factor	NULL
PU.1	NULL
binds	NULL
the	NULL
retinoblastoma	NULL
(	NULL
RB	NULL
)	NULL
protein	NULL
and	NULL
the	NULL
transcription	NULL
factor	NULL
TFIID	NULL
in	NULL
vitro	NULL
:	NULL
RB	NULL
shows	NULL
sequence	NULL
similarity	NULL
to	NULL
TFIID	NULL
and	NULL
TFIIB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:1580-1584	NULL
.	NULL

Hanazono	NULL
,	NULL
Y.	NULL
,	NULL
S.	NULL
Chiba	NULL
,	NULL
K.	NULL
Sasaki	NULL
,	NULL
H.	NULL
Mano	NULL
,	NULL
A.	NULL
Miyajima	NULL
,	NULL
K.-L.	NULL
Arai	NULL
,	NULL
Y.	NULL
Yazaki	NULL
,	NULL
and	NULL
H.	NULL
Hirai	NULL
.	NULL

1993.	NULL
c-fps/fes	NULL
protein-tyrosine	NULL
kinase	NULL
is	NULL
implicated	NULL
in	NULL
a	NULL
signaling	NULL
pathway	NULL
triggered	NULL
by	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
and	NULL
interleukin-3	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:1641-1646	NULL
.	NULL

Ip	NULL
,	NULL
H.	NULL
S.	NULL
,	NULL
D.	NULL
B.	NULL
Wilson	NULL
,	NULL
M.	NULL
Heikinheimo	NULL
,	NULL
Z.	NULL
Tang	NULL
,	NULL
C.-N.	NULL
Ting	NULL
,	NULL
M.	NULL
C.	NULL
Simon	NULL
,	NULL
J.	NULL
M.	NULL
Leiden	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Parmacek	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
GATA-4	NULL
transcription	NULL
factor	NULL
transactivates	NULL
the	NULL
cardiac	NULL
muscle-specific	NULL
troponin	NULL
C	NULL
promoter-enhancer	NULL
in	NULL
nonmuscle	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:7517-7526	NULL
.	NULL

Jucker	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
J.	NULL
Roebroek	NULL
,	NULL
J.	NULL
Mautner	NULL
,	NULL
K.	NULL
Koch	NULL
,	NULL
D.	NULL
Eick	NULL
,	NULL
V.	NULL
Diehl	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

Van	NULL
de	NULL
Ven	NULL
,	NULL
and	NULL
H.	NULL
Tesch	NULL
.	NULL

1991	NULL
.	NULL

Expression	NULL
of	NULL
truncated	NULL
transcripts	NULL
of	NULL
the	NULL
proto-oncogene	NULL
¢-fps/fes	NULL
in	NULL
human	NULL
lymphoma	NULL
and	NULL
lymphoid	NULL
leukemia	NULL
cell	NULL
lines	NULL
.	NULL

Oncogene	NULL
7:943-952	NULL
.	NULL

Klemsz	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
McKercher	NULL
,	NULL
A.	NULL
Celada	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
and	NULL
R.	NULL
Maki	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
macrophage	NULL
and	NULL
B	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
is	NULL
related	NULL
to	NULL
the	NULL
ets	NULL
oncogene	NULL
.	NULL

Cell	NULL
61:113-124	NULL
.	NULL

Lanfrancone	NULL
,	NULL
L.	NULL
,	NULL
P.	NULL
Mannoni	NULL
,	NULL
M.	NULL
J.	NULL
Pebusque	NULL
,	NULL
A	NULL
.	NULL

Care	NULL
,	NULL
C.	NULL
Peschle	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Pelicci	NULL
.	NULL

1989	NULL
.	NULL

Expression	NULL
pattern	NULL
of	NULL
c-fes	NULL
oncogene	NULL
mRNA	NULL
in	NULL
human	NULL
myeloid	NULL
cells	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
4:35-38	NULL
.	NULL

Lozzio	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
,	NULL
C.	NULL
B.	NULL
Lozzio	NULL
,	NULL
E.	NULL
G.	NULL
Bamberger	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Feliu	NULL
.	NULL

1981	NULL
.	NULL

A	NULL
multipotential	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
K-562	NULL
)	NULL
of	NULL
human	NULL
origin	NULL
(	NULL
41106	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

166:546-550	NULL
.	NULL

MacDonald	NULL
,	NULL
I.	NULL
,	NULL
J	NULL
.	NULL

Levy	NULL
,	NULL
and	NULL
T.	NULL
Pawson	NULL
.	NULL

1985	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
mammalian	NULL
¢-fes	NULL
protein	NULL
in	NULL
hematopoietic	NULL
cells	NULL
and	NULL
identification	NULL
of	NULL
a	NULL
distinct	NULL
fes-related	NULL
protein	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

5:2543-2551	NULL
.	NULL

Manfredini	NULL
,	NULL
R.	NULL
,	NULL
A.	NULL
Grande	NULL
,	NULL
E.	NULL
Tagliafico	NULL
,	NULL
D.	NULL
Barbieri	NULL
,	NULL
P.	NULL
Zucchini	NULL
,	NULL
G.	NULL
Citro	NULL
,	NULL
G.	NULL
Zupi	NULL
,	NULL
C.	NULL
Franceschi	NULL
,	NULL
U.	NULL
Torelli	NULL
,	NULL
and	NULL
S.	NULL
Ferrari	NULL
.	NULL

1993	NULL
.	NULL

Inhibition	NULL
of	NULL
c-fes	NULL
expression	NULL
by	NULL
an	NULL
antisense	NULL
oligomer	NULL
causes	NULL
apoptosis	NULL
of	NULL
HL60	NULL
cells	NULL
induced	NULL
to	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:381-389	NULL
.	NULL

Ness	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
E.	NULL
Kowenz-Leutz	NULL
,	NULL
T.	NULL
Casini	NULL
,	NULL
T.	NULL
Graf	NULL
,	NULL
and	NULL
A.	NULL
Leutz	NULL
.	NULL

1993	NULL
.	NULL

Myb	NULL
and	NULL
NF-M	NULL
:	NULL
combinational	NULL
activators	NULL
of	NULL
myeloid	NULL
genes	NULL
in	NULL
heterologous	NULL
cell	NULL
types	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:749-759	NULL
.	NULL

212.OIson	NULL
,	NULL
M.	NULL
,	NULL
E.	NULL
Scott	NULL
,	NULL
A.	NULL
Hack	NULL
,	NULL
G.	NULL
Su	NULL
,	NULL
D.	NULL
Tenen	NULL
,	NULL
H.	NULL
Singh	NULL
,	NULL
and	NULL
M.	NULL
C.	NULL
Simon	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

Submitted	NULL
for	NULL
publication	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
,	NULL
T.	NULL
Burn	NULL
,	NULL
and	NULL
D.	NULL
Tenen	NULL
.	NULL

1991	NULL
.	NULL

Optimization	NULL
of	NULL
transient	NULL
transfection	NULL
into	NULL
human	NULL
myeloid	NULL
cell	NULL
lines	NULL
using	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
.	NULL

Exp	NULL
.	NULL

Hematol	NULL
.	NULL

19:1038-1041	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
,	NULL
R.	NULL
Scheibe	NULL
,	NULL
D.	NULL
Zang	NULL
,	NULL
H.-M.	NULL
Chen	NULL
,	NULL
D.	NULL
Galson	NULL
,	NULL
R.	NULL
Maki	NULL
,	NULL
and	NULL
D.	NULL
Tenen	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
proto-oncogene	NULL
PU.1	NULL
regulates	NULL
expression	NULL
of	NULL
the	NULL
myeloid-specific	NULL
CD11b	NULL
promoter	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

7:5014-5020	NULL
.	NULL

Pongubala	NULL
,	NULL
J.	NULL
M.	NULL
R.	NULL
,	NULL
S.	NULL
Nagulapalli	NULL
,	NULL
M.	NULL
J.	NULL
Klemsz	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
R.	NULL
A.	NULL
Maki	NULL
,	NULL
and	NULL
M.	NULL
L.	NULL
Atchison	NULL
.	NULL

1992	NULL
.	NULL

PU.1	NULL
recruits	NULL
a	NULL
second	NULL
nuclear	NULL
factor	NULL
to	NULL
a	NULL
site	NULL
important	NULL
for	NULL
immunoglobulin	NULL
x	NULL
3	NULL
'	NULL
enhancer	NULL
activity	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
;	NULL
368-378	NULL
.	NULL

Rauscher	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
L.	NULL
C.	NULL
Sambucetti	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
R.	NULL
J.	NULL
Distel	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Spiegelman	NULL
.	NULL

1988	NULL
.	NULL

Common	NULL
DNA	NULL
binding	NULL
site	NULL
for	NULL
fos	NULL
protein	NULL
complexes	NULL
and	NULL
transcription	NULL
factor	NULL
AP-1	NULL
.	NULL

Cell	NULL
52:471-480	NULL
.	NULL

Ray-Gallet	NULL
,	NULL
D.	NULL
,	NULL
C.	NULL
Mao	NULL
,	NULL
A.	NULL
Tavitian	NULL
,	NULL
and	NULL
F.	NULL
Moreau-Gachelin	NULL
.	NULL

1995	NULL
.	NULL

DNA	NULL
27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

binding	NULL
specificities	NULL
of	NULL
Spi-1/PU.1	NULL
and	NULL
Spi-B	NULL
transcription	NULL
factors	NULL
and	NULL
identification	NULL
of	NULL
a	NULL
Spi-1/Spi-B	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
c-fes/c-fps	NULL
promoter	NULL
.	NULL

Oncogene	NULL
11:303-313	NULL
.	NULL

Roebrocek	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
Schalken	NULL
,	NULL
J.	NULL
Leunissen	NULL
,	NULL
C.	NULL
Onnekink	NULL
,	NULL
H.	NULL
Bloemers	NULL
,	NULL
and	NULL
W.	NULL
Van	NULL
de	NULL
Ven	NULL
.	NULL

1986	NULL
.	NULL

Evolutionarily	NULL
conserved	NULL
close	NULL
linkage	NULL
of	NULL
the	NULL
c-fes/fps	NULL
proto-oncogene	NULL
and	NULL
genetic	NULL
sequences	NULL
encoding	NULL
a	NULL
receptor-like	NULL
protein	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:2197-2202	NULL
.	NULL

Roebrocek	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
Schalken	NULL
,	NULL
J.	NULL
Verbeek	NULL
,	NULL
A	NULL
.	NULL

Van	NULL
den	NULL
Ouweland	NULL
,	NULL
C.	NULL
Onnekink	NULL
,	NULL
H.	NULL
Bloemers	NULL
,	NULL
and	NULL
W.	NULL
Van	NULL
de	NULL
Ven	NULL
.	NULL

1985	NULL
.	NULL

The	NULL
structure	NULL
of	NULL
the	NULL
human	NULL
c-fps/fes	NULL
proto-oncogene	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

42897-2903	NULL
.	NULL

Samarut	NULL
,	NULL
J.	NULL
,	NULL
B.	NULL
Mathey-Prevot	NULL
,	NULL
and	NULL
H.	NULL
Hanafusa	NULL
.	NULL

1985	NULL
.	NULL

Preferential	NULL
expression	NULL
of	NULL
the	NULL
e-fps	NULL
protein	NULL
in	NULL
chicken	NULL
macrophages	NULL
and	NULL
granulocytic	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

5:1067-1072	NULL
.	NULL

Samelson	NULL
,	NULL
L.	NULL
,	NULL
A.	NULL
Phillips	NULL
,	NULL
E.	NULL
Luong	NULL
,	NULL
and	NULL
R.	NULL
Klausner	NULL
.	NULL

1990	NULL
.	NULL

Association	NULL
of	NULL
the	NULL
fyn	NULL
protein-tyrosine	NULL
kinase	NULL
with	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:4358-4362	NULL
.	NULL

Scott	NULL
,	NULL
E.	NULL
,	NULL
M.	NULL
Simon	NULL
,	NULL
J.	NULL
Anastasi	NULL
,	NULL
and	NULL
H.	NULL
Singh	NULL
.	NULL

1994	NULL
.	NULL

Requirement	NULL
of	NULL
transcription	NULL
factor	NULL
PU.1	NULL
in	NULL
the	NULL
development	NULL
of	NULL
multiple	NULL
hematopoictic	NULL
lineages	NULL
.	NULL

Science	NULL
265:1573-1577	NULL
.	NULL

Smithgall	NULL
,	NULL
T.	NULL
,	NULL
G.	NULL
Yu	NULL
,	NULL
and	NULL
R.	NULL
Glazer	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
differentia-tion-associated	NULL
p93	NULL
tyrosine	NULL
protein	NULL
kinase	NULL
of	NULL
HL-60	NULL
leukemia	NULL
cells	NULL
as	NULL
the	NULL
product	NULL
of	NULL
the	NULL
human	NULL
c¢-fes	NULL
locus	NULL
and	NULL
its	NULL
expression	NULL
in	NULL
myelomonocytic	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263:15050-15055	NULL
.	NULL

Veillette	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Bookman	NULL
,	NULL
E.	NULL
Horak	NULL
,	NULL
and	NULL
J.	NULL
Bolen	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
CD4	NULL
and	NULL
CD8	NULL
T	NULL
cell	NULL
surface	NULL
antigens	NULL
are	NULL
associated	NULL
with	NULL
the	NULL
internal	NULL
membrane	NULL
tyrosine-protein	NULL
kinase	NULL
p56	NULL
``	NULL
*	NULL
.	NULL

Cell	NULL
55:301-308	NULL
.	NULL

Wang	NULL
,	NULL
C.-Y	NULL
.	NULL

,	NULL
A.	NULL
G.	NULL
Bassuk	NULL
,	NULL
L.	NULL
H.	NULL
Boise	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
R.	NULL
Bravo	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Leiden	NULL
.	NULL

1994	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
promoter	NULL
in	NULL
T	NULL
cells	NULL
requires	NULL
cooperative	NULL
binding	NULL
of	NULL
Elf-1	NULL
and	NULL
AP-1	NULL
transcription	NULL
factors	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:1153-1159	NULL
.	NULL

Wang	NULL
,	NULL
C.-Y	NULL
.	NULL

,	NULL
B.	NULL
Petryniak	NULL
,	NULL
L-C.	NULL
Ho	NULL
,	NULL
C.	NULL
Thompson	NULL
,	NULL
and	NULL
J.	NULL
Leiden	NULL
.	NULL

1992	NULL
.	NULL

Evolutionarily	NULL
conserved	NULL
Ets	NULL
family	NULL
members	NULL
display	NULL
distinct	NULL
DNA	NULL
binding	NULL
specificities	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:1391-1399	NULL
.	NULL

Wasylyk	NULL
,	NULL
C.	NULL
,	NULL
J.-P.	NULL
Kerckaert	NULL
,	NULL
and	NULL
B.	NULL
Wasylyk	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
novel	NULL
modulator	NULL
domain	NULL
of	NULL
Ets	NULL
transcription	NULL
factors	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

6:965-974	NULL
.	NULL

Wu	NULL
,	NULL
H.	NULL
,	NULL
K.	NULL
Moulton	NULL
,	NULL
A.	NULL
Horvai	NULL
,	NULL
S.	NULL
Parik	NULL
,	NULL
and	NULL
C.	NULL
K.	NULL
Glass	NULL
.	NULL

1994	NULL
.	NULL

Combinatorial	NULL
interactions	NULL
between	NULL
AP-1	NULL
and	NULL
ets	NULL
domain	NULL
proteins	NULL
contribute	NULL
to	NULL
the	NULL
developmental	NULL
regulation	NULL
of	NULL
the	NULL
macrophage	NULL
scavenger	NULL
receptor	NULL
gene	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:2129-2139	NULL
.	NULL

Yamanashi	NULL
,	NULL
Y.	NULL
,	NULL
T.	NULL
Kakiuchi	NULL
,	NULL
J.	NULL
Mi	NULL
hi	NULL
,	NULL
T.	NULL
Y	NULL
;	NULL
to	NULL
,	NULL
and	NULL
K.	NULL
Toyoshi	NULL
1990	NULL
.	NULL

Association	NULL
of	NULL
B	NULL
cell	NULL
antigen	NULL
receptor	NULL
with	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
lyr	NULL
.	NULL

Science	NULL
251:192-194	NULL
.	NULL

Yu	NULL
,	NULL
G.	NULL
,	NULL
S.	NULL
Grant	NULL
,	NULL
and	NULL
R.	NULL
Glazer	NULL
.	NULL

1988	NULL
.	NULL

Association	NULL
of	NULL
p93	NULL
%	NULL
*	NULL
``	NULL
tyrosine	NULL
protein	NULL
kinase	NULL
with	NULL
granulocytic/monocytic	NULL
differentiation	NULL
and	NULL
resistance	NULL
to	NULL
differentiating	NULL
agents	NULL
in	NULL
HL-60	NULL
leukemia	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

33:384-388	NULL
.	NULL

Yu	NULL
,	NULL
G.	NULL
,	NULL
T.	NULL
Smithgall	NULL
,	NULL
and	NULL
R.	NULL
Glazer	NULL
.	NULL

1989	NULL
.	NULL

K562	NULL
leukemia	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
human	NULL
c-fes	NULL
gene	NULL
acquire	NULL
the	NULL
ability	NULL
to	NULL
undergo	NULL
myeloid	NULL
differentiation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264:10276-10281	NULL
.	NULL

Zhang	NULL
,	NULL
D.-E.	NULL
,	NULL
C.	NULL
J.	NULL
Hetherington	NULL
,	NULL
H.-M.	NULL
Chen	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
macrophage	NULL
transcription	NULL
factor	NULL
PU.1	NULL
directs	NULL
tissue-specific	NULL
expression	NULL
of	NULL
the	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
receptor	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:373-381	NULL
.	NULL

